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ABSTRACT 
 
The chloroplast of eukaryotic green algae, Chlamydomonas reinhardtii, is a 
relatively new and unexplored platform for the production of human therapeutics, 
vaccines, and human monoclonal antibodies. To accurately determine the viability of 
algae as a production platform, not only does the titer of correctly folded proteins have 
to be competitive to existing platforms (insect, yeast, plants, and bacteria) but the ease of 
downstream processing must also be taken into consideration. Two proteins expressed in 
the chloroplast of C. reinhardtii were studied, a malaria vaccine candidate (Plasmodium 
falciparum surface protein 25 (Pfs25)) and a single-chained antibody fragment 
(αCD22scFv). The first part of this study (Chapter II) had two objectives: (i) increase the 
accumulation of Pfs25 and (ii) characterize the Pfs25-aggregates. By suspending algal 
cells in fresh media after 5 days of growth, the accumulation of Pfs25 increased 1.7-fold. 
The Pfs25-aggregates were separated by size exclusion chromatography (SEC) and 
found to range in size from 25 kDa to >600 kDa; even in the presence of reducing agents 
and detergent the higher molecular (MW) aggregates remained intact. Due to the wide 
variances of Pfs25, evaluating the ease of downstream processing of algae with Pfs25 
would prove to be difficult. Previously, our lab used αCD22scFv to compare three 
pretreatment methods (ammonium sulfate precipitation at pH 8.0, isoelectric 
precipitation at pH 4.5, and chitosan precipitation at pH 5.0) on residual chlorophyll, 
DNA, host cell protein, and αCD22scFv yield. However, the pretreatment methods were 
compared using anti-FLAG-affinity resin (a very specific yet highly expensive resin). 
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Therefore, the second part of this study (Chapter III) used αCD22scFv to (i) test the 
effect of pretreatment methods on αCD22scFv adsorption to Capto Q and Phenyl 
Sepharose resins and (ii) develop a purification process resulting in >98% purity. 
Isoelectric precipitation at pH 4.5 and anion exchange chromatography (AXC) 
combination was determined to be the best combination for initial recovery and 
concentration of αCD22scFv. After isoelectric precipitation and AXC, anti-FLAG-
affinity resin was the only resin scouted that showed a >98% αCD22scFv purity and 
77% yield. 
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NOMENCLATURE 
 
AP Alkaline Phosphatase 
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Ni-NTA Nickel Nitrile-Triacetic Acid 
OMPC Outer-Membrane Protein Complex 
PBST Phosphate Buffered Saline with 0.1% Tween 20 
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Pfs25 Plasmodium falciparum Surface Protein 25 
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PpL Peptostreptococcal Protein L 
RO Reverse Osmosis 
RPC Reverse-Phase Chromatography 
Rubisco Ribulose Bis-phosphate Carboxylase/Oxygenase 
scFvs Single-Chained Antibody Fragments 
SEC Size Exclusion Chromatography 
SEC-MALLS Size Exclusion Chromatography with Multi-Angle Laser Light
 Scattering 
SMFA Standard Membrane Feeding Assay 
TAP Tris-Acetate-Phosphate 
TB Transmission Blocking 
TBS-T Tris-Buffered Saline and Tween 20 
TBVs Transmission Blocking Vaccines 
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UTRs Untranslated Regions 
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CHAPTER I  
INTRODUCTION AND BACKGROUND 
 
1.1 Introduction 
Over the past 25 years, protein therapeutics has become the fastest growing 
sector in drug development.  During this period, US Food and Drug Administration 
(FDA) have approved over 130 protein therapeutics including.  These bio-therapeutics 
are produced in several heterologous protein expression systems each possessing 
advantages and disadvantages relating to ease of manipulation, cost of operation, and 
protein yield [1]. Protein-based therapeutics are produced in several different 
heterologous expression systems (mammalian, plant, and bacteria cell lines), each 
system possessing distinct advantages and disadvantages pertaining to the type of protein 
produced, the quantity and quality of protein, ease of manipulation, and cost of 
manufacture [1]. 
The chloroplast of eukaryotic green algae, Chlamydomonas reinhardtii, is a 
relatively new and unexplored recombinant production system. With simple and cheap 
growth requirements, short generation times, and a lack of human pathogens, prions, or 
other harmful toxins has shown algae to be a viable competitor to current production 
systems of recombinant therapeutic proteins. Our collaborators have shown that C. 
reinhardtii has the ability to correctly produce malaria transmission blocking vaccine 
candidate, Plasmodium falciparum surface protein 25 (Pfs25), and single-chained 
antibody fragment, αCD22scFv [2, 3]. However, to truly be demonstrated as a viable 
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production system, recombinant proteins produced in the chloroplast of algae must be 
produced and purified at a competitive cost on a commercial scale. 
This project addresses two main bioprocess challenges: (i) increasing 
recombinant Pfs25 accumulation in the chloroplast and characterize the extracted protein 
(Chapter II) and (ii) maximizing αCD22scFv purity and yield using commercial grade 
chromatographic resins (Chapter III). 
 
1.2 Background 
Utilizing microalgae as a platform for the production of recombinant protein 
production has grown in success over the past couple of decades. Human monoclonal 
antibodies [4, 5], human protein therapeutics [6], and subunit vaccines [7] have all been 
properly produced in the chloroplast of eukaryotic microalgae C. reinhardtii. However, 
there is little data available on the purification methods of the therapeutics. Because the 
most expensive portion of the total manufacturing cost of therapeutic proteins is the 
downstream processing, it is vital for recovery and purification of the protein to be 
highly selective and efficient.  
 
1.2.1 Expression systems for recombinant protein production 
The most popular expression system for producing complex proteins and 
monoclonal antibodies are transgenic mammalian cells. However, mammalian cells 
necessitate complex growth media, specialized bioreactors, have poor oxygen and 
nutrient distribution, produce waste accumulation, require a long generation time, are 
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easily contaminated by pathogens, and cells have a high sensitivity to shear stress [8, 9]. 
These limitation force scientists to search other platforms to correctly produce complex 
proteins quicker and cheaper [10]. Bacterial systems like Escherichia coli have a much 
faster doubling time than mammalian cultures, possess easily manipulated genomes, and 
are able to produce large quantities of recombinant proteins at very low cost [11]. 
Unfortunately, bacterial systems lack the machinery to properly fold complex proteins 
with disulfide bonds [12], a requirement for the correct folding of complex proteins. 
Transgenic plants, like tobacco and yeast, have also been explored as possible systems to 
produce high value proteins as they are free from human pathogens, less expensive than 
mammalian cells, resistant to most animal-infecting pathogens, and are capable of post-
translational modifications. However, there have been reports linking plant-derived 
proteoglycans to allergic reactions [13], there is a risk of environmental contamination, 
and transgenic plants have slow growth cycles [14, 15].  
Microalgae are being explored as an alternative protein therapeutic production 
platform as they have several advantages to mammalian, plant, and bacteria cell cultures. 
Compared to mammalian, plant, and bacteria expression systems, microalgae, 
specifically C. reinhardtii has several advantages as an alternative platform for 
recombinant proteins. The main advantages include: a short generation time, can be 
cultivated in enclosed bioreactors at a low cost, and possess the ability to fold complex 
human proteins due to chaperones and cellular machinery [16]. C. reinhardtii does not 
contain endotoxins, human pathogens, or any other known toxic compounds that are 
harmful to humans. Also, C. reinhardtii and several other green algae species have 
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GRAS (generally regarded as safe) status [17], permitting their formulation for  oral or 
topical delivery of therapeutic proteins. To help offset the cost of algal biomass 
production, algae could co-produce triglycerides that can be used as a potential source of 
renewable fuel. However, several challenges arise when using microalgae as the 
platform for producing high-value recombinant proteins. These include recombinant 
protein recovery, protein stability, and the use of less expensive (non-affinity) 
chromatography methods for protein purification.  All of these variables need to be fully 
understood to make an optimally-designed purification procedure. 
 
1.2.1.1 Microalgae as an expression system for high-value proteins 
The majority of current knowledge is established by using single-celled 
eukaryotic algae, C. reinhardtii, which is the most characterized genus of the microalgae 
species [18]. This strain allows recombinant proteins to be synthesized in the chloroplast, 
mitochondrial, and nuclear genomes [18]. Each genome has its own transcriptional, 
translation, and post-translational properties that make them unique. The organelle 
chosen for protein production is determined by the size and complexity of the protein 
structure along with the stability of the protein in the target site. Ideally, the location of 
protein accumulation would aid in protein functionality and ease of purification.  
If expressed in the nucleus, recombinant proteins can either be targeted to go to the 
cytoplasm or secreted out of the cell though the endoplasmatic reticulum and Golgi 
apparatus [19]. Nuclear gene expression allows regulated and tissue-specific expression, 
as well as posttranslational modifications including glycosylation [16]; however, for the 
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two proteins explored in this thesis, glycosylation of the protein will result in 
inactivation. Secretion of recombinant proteins is a common strategy in heterologous 
production systems [20, 21]. The microalgae C. reinhardtii is cultured in a water-like 
media, secretion of the proteins into the media will simplify purification as there are very 
few other impurities in the media[22]. However, recovering the secreted proteins from 
large volumes of media prove to be challenging, especially if the proteins have a small 
yield [23]. 
If proteins are synthesized in the chloroplast, they will also accumulate in the 
chloroplast. In algae grown non-photosynthetically, the chloroplast provides a protected 
intracellular space (~40% of the cell volume) that is non-essential to growth. The 
chloroplast has a higher level of accumulation than the other genomes because it is able 
to overexpress proteins and lacks gene silencing mechanisms that reduce recombinant 
protein production. Also, the chloroplast envelope may protect the protein from 
degradation [24]. Chloroplasts have multiple insertion sites and have the ability to 
process polycistronic transcripts allowing an entire gene cassette to be regulated by a 
single promoter.   
 
1.2.2 Recovery and purification of high-value proteins (native and recombinant) from 
microalgae 
During cell disruption impurities such as DNA, proteases, chlorophyll, 
polysaccharides, alkaloids, phenolics, and other host cell proteins are released into the 
lysis buffer as well as the target protein. These impurities can diminish the final product 
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quality and yield by binding to or degrading the target protein. They can also reduce the 
purification efficiency due to membrane or resin fouling. Therefore, extraction 
conditions should try to reduce the impurities from the extract while providing a safe 
environment for the protein from proteolytic degradation.  
 
1.2.2.1 Primary protein recovery by precipitation 
During protein purification, after cell lysis, the next process should rapidly 
remove the protein of interest from other proteins and macromolecules in a cell extract. 
Most often, a precipitation step is implemented after cell lysis by altering the solvent 
conditions and the solubility differences between your protein and undesired proteins in 
the extract. In this thesis, three methods of precipitation will be tested for protein 
purification: ammonium sulfate, isoelectric, and polymer.  
Knowledge of a protein’s amino acid composition is essential to determine the 
ideal precipitation method. The solubility of a protein depends on the distribution of 
hydrophilic and hydrophobic amino acids on the protein’s surface. A protein with a high 
percentage of hydrophobic amino acids on its surface will have low solubility in an 
aqueous solvent. When proteins are dissolved in a solvent, repulsive electrostatic forces 
are formed between proteins; these repulsive forces prevent aggregation and facilitate 
suspension. Solvent counterions travel towards the dissolved protein’s charged surface, 
creating a firm solvation layer. Another layer of counterions forms next to the solvation 
layer but of a lesser concentration of counterions (Figure 1).  
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Figure 1. Ordering of water molecules around hydrophobic residues on the surface of a 
protein. 
 
To induce precipitation of proteins, the solvation layer around the protein needs 
to be reduced to increase protein-protein attractive forces (Figure 2). 
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Figure 2. Protein interaction caused by disruption of hydrogen layer. 
 
Several steps need to take place before a protein precipitate forms. First, a 
precipitating agent is added to the solution and thoroughly mixed. Enough mixing time 
is required for the molecules to diffuse across the fluid eddies and allow the precipitant 
and protein to collide. Next, submicroscopic sized protein particles are generated. Under 
Brownian diffusion control, the particles will begin to grow by colliding with other 
particles until the particles reach a critical size and begin dropping out of solution.  
 
1.2.2.2 Fractionation by ammonium sulfate precipitation 
Ammonium sulfate precipitation, or salting out, is the most common method 
used to precipitate a target protein. Adding ammonium sulfate, a neutral salt, compresses 
the solvation layer and increases protein-protein interactions. The added salt interacts 
with the charges on the surface of the protein and exposes hydrophobic patches on the 
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surface of the protein, encouraging protein-protein attractive forces to surpass the 
repulsive forces between the proteins. 
 
1.2.2.3 Fractionation by isoelectric precipitation 
The isoelectric point (pI) is the pH of the solution at which the net charge of a 
protein reaches zero. In a solution with a pH below the pI of the protein, the surface of 
the protein is predominantly positively charged and creates repulsive forces between 
like-charged proteins. Likewise, in a solution with a pH above the pI of the protein, the 
surface of the protein is predominantly negatively charged and repulsion between like-
charged proteins occurs. However, at the pI the positive and negative charges cancel, 
resulting in a net charge of zero on the surface of the protein. With a net charge of zero, 
repulsive electrostatic forces are reduced and the attraction forces dominate between 
proteins resulting in precipitation of proteins (Figure 3). However, the greatest 
disadvantage of isoelectric precipitation is the irreversible denaturation of proteins. 
Therefore, this precipitation is most often used to precipitate contaminant proteins rather 
than the target protein. 
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Figure 3. Solubility of a globulin-type protein close to its pI. 
  
1.2.2.4 Fractionation by polymer precipitation 
Chitosan is a cationic linear polymer of beta-(1-4) linked D-glucosamine 
monomers is generated by chemical deacetylation of chitin [25-27]. The polymer is a 
natural polyelectrolyte that becomes charged when dissociated in an aqueous solution. 
The charge on the polymer is electrostatically attracted to the surface of proteins with the 
opposite charge, creating a bridging effect (Figure 4). Many factors affect polymer 
precipitation with the protein, including: the charge, molecular weight, and concentration 
of the polyelectrolyte, ionic strength, pH, and concentration of proteins in the solution 
[28].  
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Figure 4. Mechanism of polymer precipitation. 
 
1.2.2.5 Purification of native and recombinant proteins 
Chromatography methods have been used for the purification of 
phycobiliproteins produced and recovered from blue-green algae, Spirullina platensis, 
and red algae species, Porphyridum cruentum and Coralline elongate [29-31].  For 
purification of C-phycocyanin and allophycocyanin from Spirullina, 70% ammonium 
sulfate precipitation was used to precipitate all proteins. The pellet was resuspended and 
purified by two chromatography steps (size exclusion using Sephades G-100,  followed 
by ionic exchange process using DEAE cellulose column) [30].  
The purity (A620/A280 ratio) of C-phycocyanin reached was 2.87 with a yield of 
31 mg/g of dry S. platensis.  Likewise, 32 % of B-phycoerythrin and 12 % of  R-
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phycocyanin present in the biomass of red algae P. cruentum, were recovered and 
purified using one step anionic chromatography (DEAE cellulose column).  
Furthermore, the phycoerythrin from the Coralline elongate species was purified 
with a simple process and low cost resin (hydroxyapatite chromatography resin), which 
allowed ~ 0.06 % recovery of purified  biliprotien with a purity index of A566/A280 = 
6.67, A566/A495 = 1.44 and A620/A566 = 0.001. The ratio of the absorbance values indicate 
high purity and identity of the biliprotein with respect to other contaminant proteins in 
the sample [31].  
Large scale recovery and purification of C-phycocyanin from inferior S. platensis 
was performed in three steps using phenyl-Sepharose chromatography in an expanded 
bed adsorption column for protein recovery, followed by anion-exchange 
chromatography, and in the last step hydroxyapatite chromatography for purification 
[32]. Expanded bed chromatography with Streamline-DEAE was also tested to purify C-
phycocyanin; successfully demonstrating scalability and reduced cost [29]. 
There are only few examples of   purification of recombinant proteins produced 
in the chloroplast of C. reinhardtii and those rely on affinity tags, such as MAT and 
FLAG [2-4]. The two proteins studied in this thesis contain a FLAG-tag, making 
purification using FLAG affinity chromatography easy and highly specific [2, 4, 16]. 
Binding of the FLAG-tagged recombinant proteins is accomplished during batch binding 
on a small scale by mixing the clarified lysate and FLAG-affinity resin. After the 
recombinant proteins are absorbed onto the FLAG-affinity resin, the resin was washed to 
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remove non-specific binding proteins from the column and then eluted the FLAG-tagged 
recombinant proteins off the resin using an elution buffer at a low pH [2, 16]. 
Using FLAG-affinity resin to purify recombinant proteins from clarified lysate is not a 
scalable solution for several main factors: (i) the resin cannot handle high pressure 
necessitating the lysate to be loaded onto the column under gravity flow; (ii) the resin 
extremely expensive; and (iii) the binding capacity of the resin is only 0.6mg/mL 
requiring a large bed volume, increasing the volume of washing and elution buffers. 
FLAG-affinity resin is more suitable as an analytical tool in batch purification methods 
for FLAG-tagged proteins from cell lysates.  
Other resins will need to be scouted to identify resins that are scalable, 
economical, and provide minimal losses of the target protein. Several types of non-
affinity chromatography are available for commercial processes: reverse-phase 
chromatography, ion exchange chromatography (IEX), size exclusion chromatography 
(SEC), hydrophobic interaction chromatography (HIC), mix-mode chromatography 
columns. Pre-packed disposable chromatography columns are also possible alternatives 
to reduce production costs. 
 
1.3 Objectives 
The overall objective of this research is to further investigate the practicality of 
using the chloroplast of C. reinhardtii as a competitive production system for 
recombinant proteins. This project will characterize high molecular weight Pfs25 
proteins reported by Mayfield and Vinetz’s laboratories [2, 33]. Then, a purification 
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process on αCD22scFv will be designed using pretreatment methods explored previously 
by our lab [34]. The specific objectives of this research are: 
1. Increase Pfs25 accumulation in the chloroplast of C. reinhardtii. 
2. Determine the size and stability of Pfs25-aggregates. 
3. Compare effects of pretreatment methods on αCD22scFv adsorption to Capto Q 
and Phenyl Sepharose resins.  
4. Scout Phenyl Sepharose and hydroxyapatite resins as possible intermediate 
chromatography steps. 
5. Determine purity and yield of αCD22scFv after isoelectric precipitation at pH 
4.5, anion exchange chromatography, and FLAG-affinity polishing step. 
 
1.4 Thesis organization 
This thesis is arranged into chapters. Each chapter begins with an introduction of 
the main findings concerning the specific chapter; followed by previous work and the 
purpose of the study. A material and methods section follows the introduction in 
Chapters II and III and is concluded with a presentation of the results and a discussion of 
the main findings. 
Chapter I: titled “Introduction and literature review” begins with an introduction 
of the overall work presented in this thesis. A literature review covering basic concepts 
and background of the topics studied follows the introduction. Chapter I concludes with 
objectives and organization of the thesis. 
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Chapter II: titled “Increased accumulation and characterization of Pfs25 
produced in chloroplast of Chlamydomonas reinhardtii” includes a literature review on 
the progression of Pfs25 expression and purification. This chapter focuses on purifying 
and characterizing Pfs25 from the chloroplast of C. reinhardtii as a possible “model” 
protein to evaluate downstream processing technology. 
Chapter III: titled “Development of a purification train for recombinant protein 
produced in C. reinhardtii” beings with a literature review on the single chain antibody 
fragment (αCD22 scFv) along with previous work on different primary recovery 
methods for clarification of algae extract. This chapter evaluates the effectiveness of 
different primary recovery methods on further downstream processing. 
Concluding the thesis, chapter IV: titled “Conclusions and recommendations” 
states the main findings of the study and recommendations for future work. 
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CHAPTER II 
INCREASED ACCUMULATION AND CHARACTERIZATION OF PFS25 
PRODUCED IN THE CHLOROPLAST OF CHLAMYDOMONAS REINHARDTII 
 
2.1 Overview 
Decades of research have been devoted to the development of a malaria vaccine 
that not only addresses morbidity but the transmission of the disease as well. One of the 
leading transmission blocking vaccines (TBVs) is the Plasmodium falciparum surface 
protein 25 (Pfs25). Due to the high cost of vaccines, various expressions are being 
explored to successfully produce active vaccines at the lowest price possible. Algae is an 
attractive and relatively unexplored production platform because of its simple and 
inexpensive growth requirements, short generation time, and absent of human pathogens, 
prions, or other harmful toxins. The chloroplast of Chlamydomonas reinhardtii has been 
proven to successfully fold recombinant proteins, including the complex structure of 
Pfs25. Steven Mayfield and Joseph Vinetz’s laboratory both reported high molecular 
weight bands seen on Western blots when reacted with Anti-Pfs25-4B7 monoclonal 
antibody (mAb). This current study is aimed at enhancing the current production level of 
Pfs25 1.7-fold by resuspending the culture in fresh media before light induction. Also, 
the Pfs25-aggregates were characterized and found to range from 25 to 600 kDa in size. 
The aggregates proved to be stable in the presence of reducing agents and detergents. 
Thus, the chloroplast of C. reinhardtii is a promising production platform for Pfs25 and 
the aggregates should be further investigated for possible immunogenicity and TBA. 
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2.2 Introduction 
2.2.1 Malaria disease  
Malaria is an infectious and parasitic disease that has claimed the life of millions 
of children and adolescents, the leading cause of morbidity and mortality worldwide. 
Rainfall, consistent high temperatures, high humidity, and stagnant waters provide a 
breeding ground for mosquitos in tropical and subtropical regions. In poverty-stricken 
countries, there are limited resources to combat the disease, resulting in many lives lost. 
Without a proper labor force, the country is unable to develop, preventing the country 
from growing economically, keeping the country poor and unable to buy supplies to 
keep their citizens disease free (a vicious cycle). Many attempts to eradicate malaria 
have been made over the past couple hundred years, starting with natural remedies and 
evolving to sophisticated medicinal therapies. Since the 1600s, quinine, a material 
acquired from the bark of a cinchona tree, has been known to be effective against 
malaria [35]. After the transmission of malaria was better understood, scientists believed 
that by focusing on destroying the vector the cycle of infection could be halted. Thus, 
DDT and other insecticides began being used to kill mosquitoes; however, insecticide-
resistant mosquitoes and drug-resistant parasites have forced the development of malaria 
vaccines.  
To completely eradicate malaria, the life cycle of the disease must be fully 
understood. Malaria is caused by the parasite Plasmodium, a single-celled organism that 
has multiple life stages and requires more than one host for its survival. When a 
mosquito infected with malaria feeds on a human, the parasite, in the mosquito’s saliva 
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glands, enters the human’s body as a sporozoite. The sporozoite travels directly to the 
human’s liver where it infects the liver cells and undergoes rounds of asexual 
reproduction to produce merozoites; one sporozoite can asexually reproduce to form 
40,000 merozoites. A high concentration of merozoites can seriously challenge a 
human’s immune system’s ability to battle the parasite. The merozoites leave the liver 
and enter into the bloodstream and infect healthy red blood cells. In the red blood cells, 
the merozoites asexually reproduce hundreds of new merozoites. The merozoites burst 
the red blood cell and are released back into the blood stream, infecting more healthy red 
blood cells. It is during this phase that some merozoite-infected blood cells will stop 
asexually reproducing and instead mature into sexual forms of the parasite: male and 
female gametocytes. When a female Anopheles mosquito ingests the gametocytes during 
a blood meal, the gametocytes form gametes upon entering the midgut of the mosquito, 
which then fuse to form zygotes and are then transformed into elongated motile 
ookinetes. The ookinetes cross the mosquito’s midgut and are transformed into spherical 
oocysts. Every surviving oocyst produces thousands of sporozoites which migrate to the 
mosquito’s salivary glands and infect another human host during the next blood meal 
[36]. Malaria vaccines are being developed against different stages in the parasite’s life 
cycle: sporozoite also referred to pre-erythrocytic (the liver stage, or the stage before the 
parasite infects red blood cells), asexual (when the parasite is infecting red blood cells), 
and sexual stage (when the parasite has been taken up by the mosquito during a blood 
meal and is being reproduced in the midgut of the mosquito) [37]. Sporozoite vaccines 
are designed to prevent mosquito-induced infection [38]. Targeting the asexual stage is 
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designed to prevent infection and to reduce disease severity. However, targeting the 
sexual stage blocks the transmission of the disease from mosquito to human hosts by 
inducing antibodies in the human host [37].  
Even though there are several different anti-malaria drugs are under development 
targeting different stages of the parasite, there are many hurdles for the vaccine 
candidates to become a viable tool against the eradication of malaria. The countries that 
have a high rate of mortality due to malaria do not have many proper medical facilities 
and many citizens do not have access to them, either due to money or distance to the 
facility. Therefore, there is a great need to produce a malaria vaccine that is low cost and 
scalable production, with high, correctly folded, protein yields. The vaccine must also be 
able to travel long distances, without refrigeration, without losing its specificity. Then, 
once the vaccine arrives at its destination, it must be easily administered, either orally as 
a heat-stable capsule or as a nasal-spray, to prevent further infections due to 
misadministration or poor hygiene. The successful vaccine must completely adhere to all 
of these criteria.  
Two main malaria vaccines have been developed by scientists, each targeting 
different life stages of the parasite: the sporozoite and sexual stage of the parasite 
(unfortunately there are no successful vaccines that target the asexual stage). The RTS,S 
vaccine is a vaccine that targets the sporozoite stage of the parasite’s life cycle. The aim 
of this vaccine is to either prevent the sporozoites from entering into the liver cells or to 
destroy infected liver cells. RTS,S is in Phase III of clinical trials and have had very 
promising results. Children ages 5-17 months showed a reduced risk of clinical malaria 
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and severe malaria by 56% and 47%, respectively [39]. However, in infants ages 6-12 
weeks only 33% had fewer episodes of both clinical and severe malaria [40]. Currently, 
scientists are working on improving the efficacy of the RTS,S vaccine to at least 50% 
effective by employing boost technology, adjuvants, and antigen optimization. The 
second vaccine is known as a transmission blocking vaccine (TBV), developed to 
prevent the sexual stage parasites from undergoing successful sporogonic development 
in the midgut of mosquitoes, stopping the transmission from human to mosquito and 
subsequent spread of the parasites [41]. One TBV candidate vaccine, Pfs25-EPA, is 
being developed by US National Institute of Allergy and Infectious Diseases Laboratory 
of Malaria Immunology and Virology and Johns Hopkins University Center for Vaccine 
Research. TBVs do not directly protect vaccinated individuals from infection; they only 
contribute to elimination of the disease. Therefore, by combining TBVs with vaccines 
targeting other stages of the infection the transmission of parasites that have escaped the 
immune response could be better prevented [42]. Recently, the Malaria Eradication 
Research Agenda Consultative Group on Vaccines has set as a core goal that any malaria 
vaccine program needs to reduce transmission as well as morbidity [43]. Therefore, only 
vaccines targeting the sexual stage of the parasite are being investigated in this study. 
There are five species of the parasite known to cause disease in humans: 
Plasmodium falciparum, P. vivax, P. ovale, P. malariae, and P. knowlelsi. Of the five 
Plasmodium species, P. falciparum causes the highest mortality rate and P. vivax causes 
the highest morbidity rate. Even though all the species of the parasite must be addressed 
to completely eliminate malaria, only TBV candidates targeting P. falciparum will be 
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studied. The long-term success of a TBV depends upon induction of high functional 
antibody titers in order to effectively block the parasite transmission cycle. In P. 
falciparum three antigens have been identified whose antibodies have the ability to 
effectively reduce malaria transmission: Pfs230, Pfs48/45, and Pfs25 [44-49]. Of the 
three target antigens, Pfs25 has shown the most significant progress in clinical trials. 
Pfs25, with a molecular mass Mr 25,000 (25K), is the leading TBV candidate. 
This protein is expressed on the zygotes and ookinetes during the sexual stage of the P. 
falciparum life cycle. Pfs25 is a flat triangular molecule having four epidermal growth 
factor (EGF)-like motifs. The vaccine also possesses 22 conserved cysteines in the 
oxidized form creating eleven disulfide bonds buried within the protein [36] (a crucial 
element in the stability of this surface protein). Most importantly the protein possesses a 
C-terminal glycosylphosphatidylinositol (GPI) moiety anchoring the protein to the 
parasite surface [47, 50, 51]. Therefore, the protein must remain un-glycosylated to 
maintain its activity. 
 
2.2.2 Production systems for Pfs25  
The first platform explored as a possibility of producing Pfs25 was Escherichia 
coli, chosen for its ease and low overall costs. The bacteria produced an abundant 
amount of recombinant protein in the form of inclusion bodies. However, the 
transmission blocking antibodies to Pfs25 did not recognize the resulting fusion protein, 
revealing that the important conformational target epitopes were not recreated. Pfs25 
was injected into mice and rabbits to determine if the protein would provoke an immune 
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response. The animals elicited antibodies that recognize the native protein; however, it 
failed to block transmission [52]. However, very recently, codon harmonization of the 
coding-gene sequence has allowed scientists to successfully express and purify 
recombinant Pfs25 protein from inclusion bodies upon resolubilization and successful 
refolding. Codon-harmonized recombinant Pfs25 elicited high titers of specific 
antibodies capable of recognizing Pfs25 protein in the mosquito midgut along with 
potent TBA in mice [53].  
The first efforts to produce large quantities of recombinant Pfs25 were made 
using Saccharomyces cerevisiae in 1991 in California [48]. Barr et al. removed the 
glycosylation sites of the encoded protein to facilitate secretion from the yeast; this 
protein was labeled as Pfs25-B. The protein was purified using ion-exchange 
chromatography (IEX) on Fast Flow Q resin then by gel filtration on S-100 HR 
Sepharose. The purified protein was analyzed by immunoblotting using rabbit polyclonal 
antisera to Pfs25 and with mAb 1C7, a transmission blocking (TB) mAb that only 
recognizes natural Pfs25 under nonreducing conditions. The purified protein was 
conjugated with the muramyl tripeptide (MTP) adjuvant MF59 to immunize mice and 
monkeys. Even though Pfs25-B was only partially conformationally correct (based on 
weak interactions with mAB 1D2 and P7), the protein was still able to elicit TB 
antibodies in both the mice and monkeys. Kaslow continued Barr’s work and adsorbed 
Pfs25-B to alum to induce TB antibodies in both mice and monkeys [54]. He also 
reported that the antisera to Pfs25-B adsorbed to alum appeared to block the in vivo 
development of zygotes to ookinetes, compared to mAbs to Pfs25 which block 
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transmission only after ookinete development. To overcome potential production 
problems with Pfs25-B, three modifications were made to create a second generation 
malaria TBV candidate:(1) the last cysteine residue of the fourth EGF-liked domain was 
added back in, (2) three of the four potential N-linked glycosylatin sites were mutated by 
substituting glutamine for asparagine residues, and (3) a six histidine tag was added to 
the carboxy-terminus for ease of purification and detection [55]. Because the 
transmission-blocking vaccine was based on Pfs25 with a histidine tag, the protein was 
renamed TBV25H. Affinity chromatography using a nickel nitrile-triacetic acid (Ni-
NTA) agarose resin and Sephadex-75 size exclusion chromatography (SEC) was used to 
achieve highly purified TBV25H. After three doses of 5 µg alum-adjuvanted TBV25H, 
the mice developed Abs to TBV25H and elicited TBA, significantly suppressing oocyst 
development [55]. TBV25H vaccine candidate was tested on mice, rabbits and monkeys, 
all of which induced TB Abs [49, 54, 56]. After taking TBV25H to Phase I clinical 
trials, it was found that humans elicited an immune response, but the antibody titers were 
too low to continue [57]. It was hypothesized that the Phase I clinical trials in humans 
were unsatisfactory because Pfs25H, purified by Ni-NTA chromatography, was a 
mixture of two structural conformers, Pfs25H-A and Pfs25H-B. Zou et al. further 
purified the secreted protein using Ni-NTA Superflow, phenyl Sepharose hydrophobic 
interaction chromatography (HIC) column, and a Superdex 75 SEC to separate the two 
conformers [58]. Only ScPfs25H-A was strongly recognized by conformation-dependent 
mAbs, 1D2 and 4B7, and it elicits TB antibodies in mice. However, Pfs25H-A is less 
than 1% of the total Pfs25H; therefore, to improve the production levels of Pfs25H-A, 
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the recombinant protein was produced and secreted from the yeast Pichia pastoris, 
PpPfs25H-A. Identical to S. cerevisiae, two structural conformers were produced and 
purified in P. pastoris. Even though the yield of PpPfs25H is comparable to ScPfs25H, 
60% of PpPfs25H is the correctly-folded PpPfs25H-A (characterized using monoclonal 
anti-Pfs25H antibody 1D2 and 4B7) [58]. When PpPfs25H-A proceeded to Phase I 
human trials, with Montanide ISA 51 as an adjuvant, the vaccine elicited significant 
antibody titers and high levels of TBA in the human volunteers [59]. However, there 
were several cases of erythema nodosum and leukemoid reactions causing the trials to 
cease [59]. Montanide ISA 51 was previously believed to be generally well tolerated in 
human trials, but because of the adverse effects of PpPfs25/ISA 51, only human use-
compatible adjuvants are being considered as possible carrier proteins. A series of 
studies were performed to improve the immunogenicity and TBA of PpPfs25H-A by 
chemically conjugating the protein to different carrier proteins. PpPfs25H-A was 
chemically conjugated to the outer-membrane protein complex (OMPC) of Neisseria 
meningitidis serogroup B by Wu et al.; they reported the induction of high, continual 
levels of Ab responses in mice, rabbits, and rhesus monkeys [60]. It was also reported 
that there was a rapid boost response in rhesus monkeys (already primed with PpPfs25H-
OMPC) with nonconjugated PpPfs25H [60]. At the same time, Kubler-Kielb et al. 
reported that by conjugating PpPfs25H to itself, recombinant Pseudomonas aeruginosa 
endotoxin A, or ovalbumin, long-lasting and high levels of TB antibodies were induced 
in mice after three injections (2.5 µg Pfs25 conjugate per injection) [61]. Qian et al. 
conjugated PpPfs25H to the mutant, nontoxic Pseudomonas aeruginosa ExoProtein A 
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(EPA) and reported a 1,000-fold increase in Ab titers and significantly higher TBA in 
mice after two injections of only 0.5 µg of PpPfs25-EPA [62]. To further the initial 
results of Qian et al., Shimp et al. characterized PpPfs25-EPA to better understand its 
potential for increased immunogenicity and its safety profile in humans [63]. Shimp 
found that the soluble PpPfs25-EPA conjugate appeared to be a spherical nanoparticle 
(~600kDa) and increased specific Abs in mice 75-110 fold when adsorbed on 
Alhydrogel® [63]. By adding CPG 7909 to PpPfs25-EPA conjugates formulated on 
Alhydrogel®, the specific antibody responses in mice further increased, resulting in Ab 
levels much higher than what was required for TBA [64]. PpPfs25-EPA, administered 
with Alhydrogel® was administered to humans in a Phase 1 clinical trial [65]. It was 
seen that Pfs25-EPA/Alhydrogel was well tolerated in humans and increased the 
immunogenic response with each successive dose, inducing Ab titers that correlated with 
TBA [65]. 
Through extensive studies, it was found that P. falciparum has is unable to form 
N-glycosylations and O-linked glycosylation is almost undetectable [66, 67]; therefore, 
the addition of N- or O-linked carbohydrates on recombinant malaria vaccine proteins is 
undesirable. Even though the N-glycosylation sites were removed from Pfs25 to 
facilitate secretion from yeast, the level and position of O-glycosylation in P. pastoris is 
impossible to predict due to the mannose residues added to the protein while moving 
through the endoplasmic reticulum (ER). The Malaria Vaccine Development Branch at 
the National Institute of Allergy and Infectious Disease in the US showed that 
overproduction of P. pastoris protein disulfide isomerase significantly reduced the level 
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of glycosylation in Pfs25 while also increasing the quantity of Pfs25 secreted by 3-fold, 
providing evidence of unintended glycosylation of Pfs25 in P. pastoris [68]. To enhance 
the immunogenicity with long-lasting TBA of the vaccine candidate and prevent O-
linked glycosylation due to Pfs25 moving through the ER, the Fraunhofer USA group 
successfully produced four recombinant, full-length, 6× His-tagged Pfs25 proteins 
produced in Nicotiana benthamiana (non-secreted): (1) a glycosylated (wild-type) 
protein (Pfs25F1E), (2) a non-glycosylated (mutant) protein (Pfs25MF1E), (3) a 
glycosylated protein fusion to the modified lichenase carrier molecule (LicKM) 
(Pfs25F3E), and (4) a non-glycosylated protein fusion to LicKM (Pfs25MF3E) [69]. 
After immobilized metal affinity chromatography (IMAC), IEX, and hydrophobic 
interaction chromatography (HIC), the purified protein was analyzed by SDS-PAGE and 
an immunoblot probed with an anti-His mAb, both revealing one prominent band. The 
biochemical and biophysical characterization of the Pfs25 constructs was analyzed by N-
terminal sequencing, in vitro de-glycosylation reactions, electrospray ionization mass 
spectroscopy (MS) mass determination, Coomassie-stained SDS-PAGE, and size-
exclusion chromatography combined with multi-angle laser light scattering (SEC-
MALLS) to show that each construct had greater than 90-95% purity. Serum samples 
from immunized mice were analyzed by ELISA for Pfs25-specific IgG responses and 
TBA was determined by running a standard membrane feeding assay (SMFA) on the 
serum samples. It was determined that mice immunized with Pfs25MF1E, Pfs25F3E, or 
Pfs25MF3E with Alhydrogel® as an adjuvant generated Abs that resulted in 97-100% 
reduction in the number of oocysts and mean oocyst reduction of 47% [69]. By 
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introducing mutations into the LicKM carrier molecule, the non-glycosylated version of 
the Pfs25-based subunit vaccine, Pfs25-FhCMB, was further optimized [70]. Pfs25-
FhCMB was purified using a three-column chromatographic method: IMAC, HIC, and 
IEX. Analysis by SDS-PAGE under reducing conditions revealed a single band; 
analytical reverse-phase chromatography (RPC) provided a ≥95% purity; and target 
identity was confirmed by western blotting using anti-Pfs25, anti-LicKM, and anti-
4×His Abs. Serum samples were tested for Pfs25-specific IgG responses using ELISA 
and for TBA using SMFA. These tests proved that Pfs25-FhCMB elicits long-lasting and 
potent TBA in mice and rabbits [70]. 
 Microalgae C. reinhardtii offers several advantages to current TBV expression 
systems. Not only are they generally recognized as safe (GRAS) by the US Food and 
Drug Administration (FDA), inexpensive, and easily scalable, but their lack of human 
pathogens, prions, or other harmful toxins reduces the risk of residual contamination 
following purification. Mayfield’s lab in San Diego, California demonstrated that the 
chloroplast of C. reinhardtii could produce correctly folded Pfs25 that was recognized 
by TB mAb, 4B7 [2]. This was accomplished because the chloroplast lacks the 
machinery for post-translational glycosylation (a huge advantage for production of 
Pfs25) and contains nuclear encoded chaperones that assist in the correct folding of the 
complex EGF-like domains [71]. To overcome the poor immunogenicity of Pfs25, 
Gregory fused Pfs25 with cholera toxin beta subunit (CTB) and orally delivered the 
fusion to BALB/c mice. CTB-Pfs25 elicited CTB specific IgG antibodies and secretory 
IgA antibodies to both CTB and Pfs25. However, Pfs25 IgG antibodies are needed for 
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TBA during a mosquito blood meal, not IgA. Therefore, different adjuvants need to be 
explored to increase Pfs25-specific IgG antibodies. Due to erythema nodosum and 
leukemoid reactions being observed in humans during the Phase I clinical trial of 
Montanide ISA 51 oil-in-water adjuvant [59], only human use-compatible adjuvants are 
being explored, regardless of the heterologous expression system. Joseph Vinetz’s 
laboratory compared rPfs25 with four different human compatible adjuvants (alum; 
TLR4 agonist (glucopyranosal lipid A, GLA) plus alum; squalene oil-in-water emulsion; 
and GLA plus squalene oil-in-water emulsion) and compared their ability to induce 
malaria TBAs. They found that rPfs25 plus GLA plus squalene oil-in-water adjuvant 
induced the highest titer and avidity IgG antibodies [33]. Vinetz reported a Western 
immunoblot of affinity purified Pfs25 reacting with 4B7 (anti-Pfs25) at 25, 50, and 75 
kDa markers, under non-reduced conditions; Gregory also reported that even higher 
molecular weight proteins were found in the purified sample, between 100 and 130 kDa, 
under the same conditions [2, 33]. Based on the data indicating that self-conjugated 
Pfs25 as well as other conjugated constructs elicit a higher immunogenic response than 
Pfs25 monomeric form, in this study we extended the work of Gregory et al. (2012) and 
Vinetz et al. (2015) with the objectives to increase accumulation of Pfs25 in C. 
reinhardtii biomass and characterize Pfs25-produced protein forms (aggregates).  
 
 
 
 
 29 
 
2.3 Materials and methods 
2.3.1 Gene constructs for Pfs25 
The Pfs25 gene construct was designed by our collaborators at the University of 
California in San Diego. In the construct, the endogenous psbA locus was replaced by 
Pfs25 by direct homologous recombination. Thus, transgene expression in these strains 
is regulated by the psbA promoter and the 5’ and 3’ untranslated regions (UTRs) and, 
therefore, is light inducible. A kanamycin resistance cassette was incorporated for 
selection. The gene cassette was ligated with a sequence coding for a 1xFLAG peptide 
(DYKDDDDKS) and separated by a sequence that encodes a tobacco etch virus (TEV) 
protease cleavage site (ENLYFQG) [71]. 
 
2.3.2 Cultivation of recombinant Pfs25 Chlamydomonas reinhardtii strains  
Algal biomass from a single agar plate (Tris-Acetate-Phosphate (TAP) agar with 
150 μg/mL kanamycin) was transferred to 100 mL of TAP media without kanamycin 
and grown for 3 days. A subsequent volumetric culture scale up was performed using 
10% inoculum in the exponential phase (100 mL) in 1 L of fresh TAP media containing 
25 μg/mL kanamycin. One-liter cultures were grown heterotrophically for 5 days, 
reaching ~4 to 5 × 10
5
 cells/mL. For resuspension experiments at the end of the fifth 
day, the biomass from 1-L cultures was resuspended in 1-L of fresh TAP media 
containing 25 μg/mL kanamycin and grown for 1 day, reaching about 106 cells/mL. The 
latter cultures were then exposed to light at a photon irradiance of 300 µmol m
-2
 s
-1
 to 
induce recombinant protein synthesis. Control experiments without resuspension were 
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performed under the same time and light regimes. For each recombinant protein, three 
replicate batches were grown in different conditions (resuspension vs. non-resuspension) 
followed by light induction. Cell growth and cell concentration were monitored daily by 
counting cells using a hemocytometer (Bright Line, Hausser Scientific, Horsham, PA, 
USA) and by measuring the optical density at a 750-nm wavelength using a DU640 
spectrophotometer (Beckman Coulter, Brea, CA, USA). 
 
2.3.3 Protein Extraction  
C. reinhardtii cultures producing recombinant proteins were grown in liquid 
media until they reached the desired cell concentration of ~10
6
 cells/mL. At the end of 
the light exposure period, cells were harvested by centrifugation at 10,000× g for 15 min 
at 4°C. Pelleted algal biomass was washed with fresh TAP media, weighed and then 
resuspended at a 1:5 biomass-to-lysis buffer ratio (50 mM Tris-HCl, 400 mM NaCl and 
0.5% Tween, pH 8.0). The buffer contained a complete protease inhibitor cocktail 
(Roche, Mannheim, Germany) dissolved in 200 mL of the buffer. Algal cells were lysed 
by sonication for 8 min with 30 s on/off intervals at 4 °C using a sonicator (Sonifier 250, 
Branson, Danbury, CT, USA) at 30% output control and 30% duty cycle with a micro 
probe (1/8” microtip A3-561 Branson, Danbury, CT, USA). Cell lysates were 
centrifuged (10,000× g for 10 min) to produce clarified crude extracts. 
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2.3.4 Protein Analysis 
Filtered algal crude extract and purified samples were analyzed by SDS-PAGE 
and Western blot, and the total eluted protein was determined by the Bradford assay 
[18]. Total soluble protein from crude extracts and purified samples were quantified 
using the microplate protocol (working range from 1 to 25 μg/mL and 25 to 1,500 
μg/mL) Coomassie plus (Bradford) assay kit (Thermo Scientific, Waltham, MA, USA). 
Absorption at 595 nm was measured using the VERSA max microplate reader 
(Molecular Devices, Sunnyvale, CA, USA).  
NuPAGE Novex Bis-Tris pre-cast gradient gels (4%–12%) from Invitrogen™ 
(Carlsbad, CA, USA) (1.5 mm × 10 wells), were used for SDS-PAGE electrophoresis. 
Reducing buffer was prepared using lithium dodecyl sulfate (LDS) sample buffer (4×) 
(NuPAGE) containing 10% of reducing agent. Reduced samples were prepared using a 
1:4 reducing buffer to sample ratio and heated at 70 °C for 10 min. MES SDS Running 
Buffer (20×) stock solution was used to prepare 1× running buffer in reverse osmosis 
(RO) water. Antioxidant (NuPAGE, Invitrogen™, Carlsbad, CA, USA) was added to 
ensure reduced samples during electrophoresis. Gels were run for 35 min at a constant 
voltage (200 V). For SDS 25 analysis, the gels were blocked with a solution of 50% RO 
water, 40% ethanol, 10% acetic acid for 45 minutes. Then, the gels are rinsed with RO 
water and stained in Coomassie™ (Thermo Fisher Scientific, Waltham, MA, USA) G-
250 stain for 3 hours. The gels are finished by destaining in RO water. For western blot 
analysis, the gel was transferred to nitrocellulose membranes using the iBlot® 7-Minute 
Blotting System, Life Technologies Corporation (Carlsbad, CA, USA). 
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After protein transfer to a nitrocellulose membrane, the membrane (free sites) 
was blocked with 2.5% non-fat milk in TBS containing 0.05% Tween 20 at pH 7.5 
buffer for 1 h to prevent nonspecific binding of the detection antibodies. FLAG-tagged 
recombinant proteins (αCD22scFv and Pfs25) were detected by using anti-FLAG M2-
AP (alkaline phosphatase conjugated) antibody from Sigma Aldrich (St. Louis, MO, 
USA) at a concentration of 1:2000. After incubation with the antibody for 1 h, the 
membrane was washed with TBS containing 0.05% Tween 20 at pH 7.5; buffer and 
blots were visualized (developed) with nitro-blue tetrazolium (NBT) and 5-bromo-4-
chloro 3‟-indolyphosphate p-toluidine salt (BCIP) (Sigma FAST, St. Louis, MO, USA) 
dissolved in 10 mL of filtered RO water. 
 
2.3.5 FLAG-affinity capture and purification  
Crude extracts were filtered using a polyethersulfone (PES) 0.45-μm filter and 
mixed with anti-FLAG affinity resin (Sigma Aldrich A4596, St. Louis, MO, USA) 
equilibrated in the same lysis buffer used for protein extraction. Approximately 1 mL of 
resin was used per every 4 g of wet algal biomass. Binding of the recombinant protein to 
the affinity resin was performed for 2 h at 4 °C by continuous end-over-end mixing in a 
Glas-Col rotor (Glas-Col LLC, Terre Haute, IN, USA) at ~33 rpm (40% speed control). 
After the incubation period, the affinity resin was transferred into Bio Spin disposable 
chromatography columns (Bio Rad, Cat No. 732-6008, Hercules, CA, USA) for protein 
elution at room temperature. Affinity resin was washed with 10 column volumes (CVs) 
of lysis buffer without Tween 20. Recombinant protein was eluted using 5 CV of 100 
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mM glycine buffer, pH 3.5, which contained 400 mM NaCl. Eluted protein fractions 
were collected in 5 tubes containing a predetermined amount of 1M Tris-HCl, pH 8.0, to 
immediately increase the pH of the eluted protein and avoid protein denaturation. 
Typically, three elution fractions (E2 to E4) were used for the estimation of purity and 
yield, although some losses occurred by not taking into account E1 (Elution Fraction 1). 
By pooling these three fractions, more than 80% of extracted FLAG-tagged proteins 
were recovered. Extraction buffer and all of the materials used, including the sonication 
probe (1/8” microtip A3-561 Branson, Danbury, CT, USA), were cooled in advance. 
The FLAG affinity adsorption and elution was used as a convenient analytical 
tool to determine the recombinant extraction yield. The resin was added in sufficient 
amounts to bind all available FLAG fusion protein present in clarified extracts. Cell 
debris and supernatants at the end of the batch adsorption period were regularly analyzed 
by western blotting to assure complete extraction and adsorption, respectively. Although 
minor recombinant protein losses have occurred during resin washing and pH 3.5 elution 
from the anti-FLAG resin, this determination of recombinant protein concentration was 
considered appropriate for estimating recombinant protein in crude extracts. 
 
2.3.6 Characterization of purified Pfs25 by SEC 
To determine the size and range of multimeric forms of Pfs25, 100 µl of 
concentrated FLAG-purified Pfs25 protein in 100mM Glycine, 400mM NaCl, pH 8.0 
buffer were loaded on a TSKgel G3000SWxl SEC (Tosho Bioscience LLC, Minato, 
TKY) at a flowrate of 0.5 mL/min.  
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Analysis of FLAG-purified Pfs25 by anion exchange chromatography was 
performed using CIM QA monolith disk (BIA Separations d.o.o., Ljubljana, SVN) at a 
flowrate of 3 mL/min. The monolith disk was washed with 10 CVs of 20mM Tris pH 8.0 
and bound protein eluted with a 20 CV gradient to 100% 20mM Tris, 0.7M NaCl, pH 
8.0. 
Two-dimensional gel electrophoresis of FLAG-purified Pfs25 samples was done 
by Texas A&M Protein Chemistry Lab.   
 
2.3.7 ELISA 
Selected fractions of FLAG-purified Pfs25 separated by SEC were diluted 2, 4, 
and 8-fold with RO water, with triplicates of each dilution. NUNC-Immuno™ 
MicroWell™ Maxisorb 96-well plate (Thermo Fisher Scientific, Waltham, MA, USA) 
were coated in triplicate with 100 µl of each diluted sample and incubated overnight at 
4°C. Wells were washed three times with Phosphate Buffered Saline with 0.1% Tween 
20 (PBST) and blocked with 3% BSA in PBS for 2 hours at room temperature. Pfs25 
was detected with 4B7 mAb (1:50 dilution) for 2 hours at room temperature followed by 
anti-mouse IgG (whole molecule)-peroxidase antibody produced in goat (Sigma Aldrich, 
St. Louis, MO, USA)  at 1:5000 for 1 hour at room temperature. Antibody binding was 
detected using the TMB substrate kit (Thermo Fisher Scientific, Waltham, MA, USA) 
and read with a Molecular Devices VersaMax reader at a wavelength of 450nm. 
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2.4 Results and discussion 
2.4.1 Cell resuspension increases Pfs25 accumulation  
From a downstream processing viewpoint, the initial concentration of target 
protein in crude lysate is of paramount importance because it directly impacts overall 
process yield and final purity of the recombinant protein.  In an earlier study using a 
different recombinant protein (αCD22scFv), our group established that suspension of 
algal cells in fresh media before light induction was beneficial to both cell concentration 
and recombinant protein accumulation.  In this work the same method was applied to 
induce higher production levels of Pfs25.  The effect of cell resuspension on final cell 
concentration (Figure 5) and Pfs25 accumulation (Figure 6) was compared to non-
resuspended control cultures. Both cultures, resuspended and non-resuspended, initially 
start with the same cell concentration (5×10
4
 cells/mL) in one liter cultures with 10% 
inoculum. The cultures follow the same growth pattern the first 5 days of growth, 
doubling in cell concentration every 2 days. The control (non-resuspended) culture 
grows for an additional 24 hours before being exposed to 101 µmolm
-2
s
-1
 of light for 24 
hours. However, after 5 days of growth, the resuspended culture was centrifuged down, 
waste media removed, and algal cells suspended in new culture media. The resuspended 
culture was then allowed to grow for 24 hours before being exposed to 101 µmolm
-2
s
-1
 
of light for 24 hours, same as control culture. The addition of fresh nutrients produced 
the intended effect on the resuspended culture by generating a 30% increase in cell 
concentration at the end of the 6 day growth period (Figure 5). Because psbA is a light 
inducible gene promotor, Pfs25 will only be produced in the chloroplast during days 6 to 
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7. Therefore, a 30% increase in cell concentration will theoretically also increase Pfs25 
production by 30%. 
 
 
 
Figure 5. The effect of cell resuspension and light exposure (100µmol m-2 s-1) on C. 
reinhardtii cell concentration and Pfs25 accumulation (% total soluble protein). Average 
of 3 replicates. TAP: Tris-Acetate-Phosphate. 
 
The amount of accumulated Pfs25 at the end of the cultivation was estimated by 
FLAG-affinity adsorption. The effect of resuspension on the amount of affinity purified 
Pfs25 is shown in lanes 8 to 10 in Figure 6. Comparing elution 2 and 3 of the two SDS-
PAGE gels (Figures 6a and 6b) it is observed that the 28 kDa band (Pfs25) is thicker and 
darker in the culture that was resuspended in fresh media on day 5. Total Pfs25 protein 
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eluted from affinity resin (Lanes 8, 9, and 10 in Figure 6) was 309 ug of protein/L 
culture for resuspended vs 133 ug/L culture for the non-resuspended control. Therefore, 
the 30% increase in cell concentration for resuspended culture resulted in a 2.3-fold 
increase in Pfs25 protein. Considering there was also a 1.3-fold increase in total host 
protein accumulation, we estimate that Pfs25 accumulation increased 1.7-fold (from 
1.5% TSP in the control to 2.5% TSP in the resuspended culture). An increase in product 
titer is always a welcome improvement because it translates more efficient downstream 
processing.  
 
 
 
Figure 6. SDS-PAGE gels of Pfs25 affinity purification from (a) non resuspended cell 
lysate (control) and (b) resuspended cell lysates. Lane 1: molecular weight marker 
(kDa); Lanes 7-10: Pfs25 eluted fractions at pH 3.5. 
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2.4.2 Purification and partial characterization of Pfs25  
Pfs25 produced in resuspended C. reinhardtii was purified by batch adsorption, 
followed by low pH elution, using anti-FLAG-affinity resin.  SDS-PAGE and Western 
blot in Figure 7 shows fractions of host cell protein and Pfs25 that were obtained during 
affinity resin washes and Pfs25 desorption. Nonspecifically adsorbed host cell protein 
was removed during the 10 CV washes before elution (Lanes 5 and 6), with Rubisco 
(~50 kDa band) being one of the most prominent protein. Based on Western blot 
analysis, the supernatant after adsorption did not possess measureable amounts of Pfs25; 
however, the wash fractions did contain detectable amounts of Pfs25 (Figure 7b), 
suggesting that a decent amount of Pfs25 was unable to specifically bind to the resin. 
The loss of Pfs25 in the wash fractions could be resolved by adding a larger amount of 
resin to the algae lysate, to provide more binding sites for Pfs25. The SDS-PAGE shows 
several minor protein bands in the elution fraction (Lanes 7-10) which are presumed to 
be Pfs25 aggregates, as indicated by the Western blot. ImageJ analysis indicates that 
about 25% of total Pfs25 in the elution lanes was aggregated.  
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Figure 7. Analysis of resin wash and eluted Pfs25 fractions. (a) SDS-PAGE gel of Pfs25 
affinity purification and (b) Western blot analysis of Pfs25 from resuspended cell lysate.  
(b) Lane 1: molecular weight marker (kDa); Lane 2: 1st CV of wash before elution; Lane 
3: 10X dilution of 1
st
 CV of wash before elution; Lane 4-5: 2
nd
 and 3
rd
 CV of wash 
before elution; Lane 7-10: elution 1-4 at pH 3.5. 
 
 
Elution fractions 2 and 3 from FLAG-affinity adsorption were pooled, 
concentrated, and run on a 2-D electrophoresis gel to determine the purity of FLAG-
purified samples (Figure 8). The 2-D gel reveals that Pfs25 sample was pure; the smear 
near bottom right-hand corner was probably lipids and/or chlorophyll pigment 
impurities. The band around the 30 kDa marker is the monomeric form of Pfs25.  The 
band spread around pI of 5.0 (The program ProtParam was used to estimate the pI as 
4.96) indicates that purified Pfs25 sample does not have a uniform isoelectric point and 
consists of several charge Pfs25 variants.   
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Figure 8. 2-D electrophoresis gel of FLAG-purified Pfs25 separated first by isoelectric 
point and then by molecular weight. 
 
2.4.3 Characterization of purified Pfs25 by SEC 
To determine the approximate amount and molecular weight (MW) distribution 
of the Pfs25 aggregates, FLAG-purified Pfs25 was analyzed by size exclusion 
chromatography (SEC) on a TSKGel G3000SWxl column. To confirm the SEC 
calibration curve developed by the column vendor (TOSOH), IgG (MW=156), BSA 
(MW=66.5kDa), and Lysozyme (MW=14kDa) were run on the same column and elution 
times recorded below (Table 1).  The retention of thyroglobulin was taken from TOSOH.  
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Table 1. Elution of calibration proteins from TSKGel G3000SWxl column from 
TOSOH. 
 
Sample MW (kDa) log (MW) Elution (ml) 
Thyroglobulin 660 2.8195439 6.7 
IgG 156 2.1931246 8.7 
BSA 67 1.8260748 9.5 
Lysozyme 14 1.146128 12.5 
 
 
 
Figure 9. Calibration curve used for analysis of Pfs25 aggregates. 
 
The resulting chromatogram of FLAG-purified Pfs25 is shown in Figure 10. 
Using the calibration curve in Figure 10, the highest MW Pfs25 aggregate seen at 6.2 
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mL elution volume translates to a >600 kDa protein. The tallest peak at 10.5 mL elution 
volume correlates with 25 kDa, representative of the monomeric form of Pfs25. 
Unfortunately, there was no baseline separation between the different aggregates that 
range from 25 to 600 kDa.  Examination of the calibration curve confirms that proteins 
beyond 60 kDa in size would be difficult to separate unless they differ in size by a factor 
of 2.  Therefore, the aggregates that were observed by SDS-PAGE of approximately 75, 
100 and 125 kDa would not be easily discernable by SEC using TSKGel G3000SWxl.  
What was surprising is the presence of species that eluted at volumes between 6 and 8 
mL because Mayfield’s laboratory and our SDS-PAGE gels only revealed Pfs25 
complexes as high as 100 to 130 kDa. The last peak on the chromatogram does not 
contain any FLAG-tagged proteins, and based on the calibration curve is ~0.3 kDa, 
probably Tween 20.  
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Figure 10. Chromatogram of Pfs25 without Tween 20 purified by anti-FLAG affinity 
chromatography separated by SEC TSKGEL G3000SWxl. 
 
To determine that early eluting fractions contain Pfs25, selected fractions were 
run on a non-reduced Western blot (Figure 11a). The non-reduced Western blot reveals 
the protein in its native form, without breaking intramolecular disulfide bonds. Only 
high molecular weight bands are seen (Figure 11a) at the beginning of the 
chromatogram; then as the chromatogram progresses, lower molecular weight proteins 
come out of the column, finishing with dark, thick bands in fraction 8 and 9 
corresponding to 28 kDa MW marker. The same samples were then run on a reduced 
Western blot (Figure 11b) to determine if aggregation pattern would change. The 
reduced Western blot, as expected, revealed that in the presence of 2-marcaptoethanol 
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and 70°C heating, Pfs25 monomer, dimer and higher MW species were released from 
the large aggregates under reducing conditions. The source or cause of the large 
agglomerates (200~600 kDa) is not clear, but one can speculate that a fraction of Pfs 
might be misfolded forming intermolecular disulfide bonds, due to disulfide bonds 2, 7, 
8, 10, and 11 of Pfs25 not being completely formed in the chloroplast [2]. 
 
 
 
Figure 11. Western blotting of FLAG-purified Pfs25 separated by SEC using anti-
FLAG-AP conjugated antibody (a) under non-reducing conditions, (b) under reducing 
conditions without Tween 20, and (c) under reducing conditions in the presence of 
Tween 20. 
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Figure 11. Continued. 
 
Because the presence of 600 kDa in the SEC chromatogram was unexpected, we 
wanted to confirm that these large aggregates were not formed solely due to hydrophobic 
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protein-protein interactions.  Therefore, 0.25% of Tween 20, was added to the FLAG-
purified Pfs25 sample, and mixed for 30 min at room temperature using an end-over-end 
rotor. The sample with Tween 20 was run on the same SEC column and the resulting 
chromatogram is shown in a Figure 13. The protein elution profile in the presence of 
Tween 20 is the exactly the same as that in the absence of Tween 20 treatment (Figure 
12). However, the peak heights of the aggregates were half on the peak height of the 
sample without Tween 20; this difference in peak height can be attributed to the dilution 
of sample with the addition of the detergent.  The tall peak at 15mL elution volume is 
the detergent coming out of the column.  Selected SEC fractions of the sample in the 
presence of Tween 20 were analyzed by a Western blot under reducing conditions 
(Figure 11c). Thus, the presence of high MW aggregates in the chromatogram was not 
an SEC product.  
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Figure 12. Chromatogram of Pfs25 with 0.25% Tween 20 purified by anti-FLAG 
affinity chromatography separated by SEC TSK GEL G3000SWxl. 
 
Another concern we had is the possibility of Pfs25 partially unfolding and 
aggregation during pH 3.5 elution, which has been often observed with low pH elution 
of monoclonal antibodies and other affinity purified proteins. Therefore, instead of using 
five CVs of pH 3.5 elution buffer, six CVs of 100 µg/mL FLAG-peptide in TBS of pH 
8.0 was used to elute Pfs25 off the FLAG-affinity resin.  Figure 13 is the SEC 
chromatogram of FLAG-peptide elution of Pfs25 at wavelength 220 nm. Even though 
FLAG-peptide elution has a different profile than regular elution method, the large 
complexes of Pfs25 are still present in the extract. It appears that Pfs25 complexes were 
not exclusively formed during the low pH elution step, although the low pH elution 
could have contributed to aggregation.  
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Figure 13. Chromatogram of FLAG-purified Pfs25 eluted using FLAG-peptide pH 8.0, 
separated using SEC. 
 
Having established that all SEC fractions cross-react with anti-FLAG 
monoclonal antibodies,  selected fractions of the SEC were probed with mAb 4B7 to 
determine which fractions were recognized by the conformationally-dependent mAb 
(Figure 14). Most of the fractions reacted with the mAb, except for Fractions 1, 12, 13, 
and 14. Fractions 1, 12, and 13 is where the chromatogram reached baseline indicating 
undetectable protein at wavelength 220nm and Fraction 14 is the detectible peak of 
Tween 20. It seems that fractions in the middle of the chromatogram (5, 7, 8, 9, 10, and 
11) have the strongest reaction with 4B7 mAb. However, the higher molecular weight 
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fractions (4 and 5) have a sharp decrease in absorbance between sample dilutions 2 and 
4. 
 
 
 
Figure 14. Reactivity of selected fractions from SEC probed with dilutions of 4B7 mAb 
on ELISA. 
 
2.5 Summary  
Our lab found that supplying fresh nutrients to cultures before light exposure 
drastically helps facilitate a more efficient downstream processing of recombinant 
proteins produced in the chloroplast of algae. Resuspending cell culture in fresh TAP 
media 24 hours before exposing the culture to light increased the cell concentration by 
30% and almost doubled the amount of Pfs25 extracted from the cells.  
SDS-PAGE analysis of FLAG-purified elutions revealed a predominant band at 
28 kDa, the gel also revealed bands at the 50, 75, 100, and 125 kDa marks. Analysis of 
the Western blot confirmed the appearance of aggregates containing Pfs25 at those 
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markers as well (identical to Gregory and Vinetz’s published results). To further 
characterize Pfs25 after extraction from the chloroplast of C. reinhardtii, FLAG-purified 
Pfs25 was run on a SEC. Using the standards for the SEC, it was determined that 
purified Pfs25 sample contained a molecular weight range from 25-600 kDa. The SEC 
fractions were run on non-reducing and reducing Western blots. The higher molecular 
weight FLAG-tagged proteins slightly break down into monomeric and dimeric forms of 
Pfs25 in the presence of reducing agents. Tween 20, a detergent, was mixed with the 
SEC fractions to ensure the aggregates were not formed due to hydrophobic protein-
protein interactions; however, the aggregates seemed to remain intact with the same 
original distribution of multimeric forms of Pfs25. Another concern of ours was that the 
low pH elution used to desorb Pfs25 off the affinity column caused the protein to 
partially unfold and aggregate, as seen with monoclonal antibodies and other purified 
protein during low pH elutions. Therefore, instead of using low pH to elute bound 
proteins off the anti-FLAG affinity column, FLAG-peptide was used to displace the 
bound proteins off the column. The FLAG-peptide eluted proteins were analyzed by 
SEC. The resulting chromatogram showed a different Pfs25 profile, but still contained a 
large range of multimeric forms of Pfs25. The low pH elution may encourage multimeric 
forms of Pfs25 to form, but high molecular weight forms of Pfs25 are present before the 
low pH elution step. When the fractions were probed with conformationally-dependent 
mAb 4B7, the middle range aggregates showed a higher reactivity compared to the 
smaller forms. 
 51 
 
The higher molecular weight FLAG-tagged proteins Gregory and Vinetz reported 
on their Western blots are in stable forms, even in the presence of detergents and 
reducing agents. The only other system that has reported self-formed Pfs25 aggregates 
was when Pfs25 secreted from P. pastoris and was chemically conjugated to EPA. 
PpPfs25-EPA was measured as a nanoparticle with a size of ~600kDa, about the same 
size as the largest aggregate found in our FLAG-purified sample. The conjugated 
protein, when administered with Alhydrogel®, was well tolerated by humans in Phase 1 
clinical trials and it elicited a strong immunogenic response with high TBA. Pfs25 
produced in the chloroplast of C. reinhardtii naturally forms large multimeric forms and 
interacts with the anti-Pfs25 mAb 4B7. Naturally formed Pfs25 aggregates are 
advantageous because additional steps to chemically conjugate the vaccine to a carrier 
protein are eliminated and there is no need to worry about the effects of the carrier 
protein during human clinical trials. The immunogenicity and TBA of the multimeric 
forms of Pfs25 need to be evaluated to further evaluate the chloroplast of C. reinhardtii 
as a possible production system for the malaria vaccine. 
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CHAPTER III 
DEVELOPMENT OF A NON-AFFINITY PURIFICATION METHODS FOR 
RECOMBINANT PROTEINS PRODUCED IN CHLAMYDOMONAS REINHARDTII 
 
3.1 Overview 
Protein therapeutics is advancing rapidly and in the past 25 years has become the 
fastest growing division in drug development. Researchers are exploring new therapeutic 
production systems depending on the size and complexity of the protein being produced. 
No matter the expression system, downstream processing accounts for a large majority 
of the total manufacturing costs of therapeutic proteins.  
Pretreatment of clarified cell lysates is the first step in downstream processing 
designed to minimize impurities before loading the lysate onto a chromatographic 
column. When dealing with intracellular products, simple clarification steps like 
centrifugation and depth filtration do not sufficiently remove soluble impurities to 
achieve downstream process robustness. Additional pretreatment methods like 
ammonium sulfate precipitation [72], isoelectric precipitation [73, 74], and polymer 
precipitation have been applied to  green tissue extracts to   remove  a significant 
fraction of host soluble protein such as ribulose bis-phosphate carboxylase/oxygenase 
(rubisco),  chlorophyll pigments and DNA  [73-75]. Polymer precipitation with cationic 
polymers, such as polyethylenimine and chitosan, has been shown to efficiently remove 
DNA.   
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Our lab previously studied the effects of the three precipitation methods 
mentioned above on the recovery of single-chain antibody fragment (αCD22scFv) [3] 
produced in the chloroplast of Chlamydomonas reinhardtii [34]. The fragment was 
recovered and quantified from clarified lysates after each pretreatment using anti-FLAG-
affinity resin. The 1M ammonium sulfate and isoelectric precipitation at pH 4.5 
pretreatments significantly reduced the percent of residual chlorophyll and host cell 
protein without significantly reducing the target protein yield. On the other hand, 
chitosan precipitation at pH 5.0 significantly reduced the percentage of residual DNA, 
chlorophyll, and host cell protein; however, there was also a significant drop in scFv 
yield. The scFv from pretreated lysates was purified using anti-FLAG-affinity resin. 
Anti-FLAG-affinity resin is not a scalable capture step for large scale purification of 
therapeutics because the resin is extremely expensive, has a low binding capacity, and is 
easily compressible.  
The objectives of this study were (i) to determine the stability of αCD22scFv 
during adsorption to Capto Q resin of, (ii) compare the effects of pretreatment methods 
on αCD22scFv adsorption to Capto Q and Phenyl Sepharose resins, (iii) scout Phenyl 
Sepharose and hydroxyapatite (HAP) resins as possible intermediate chromatography 
steps, and (iv) purify αCD22scFv using isoelectric precipitation at pH 4.5, an anion 
exchange capture chromatography, and FLAG-affinity polishing step. 
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3.2 Introduction 
3.2.1 Single-chain antibody fragments (αCD22scFv) applications  
The main line of defense against pathogenic organisms and toxins in humans are 
antibodies due to their highly specific targeting. IgG is the main serum antibody and is a 
highly complex molecule. A full-size IgG antibody is Y-shaped composed of two light 
chains and two heavy chains. Each light chain is made of a variable and constant domain 
and each heavy chain has one variable and three constant domains. There are three 
disulfide bonds total, one connecting each heavy chain to a light chain and one 
connecting the two heavy chains. The variable regions on the tips of the light chain 
define antigen specificity of the antibody [76]. Engineered monoclonal antibodies 
(mAbs) are already on the biotechnology market and more are on their way in clinical 
trials. To date, twenty-two mAbs have been approved in the US for therapeutic use and 
account for $20 billion of healthcare spending [77]. Currently, the market is dominated 
by mAb products composed of the full-size form of IgG but smaller single-chained 
antibody fragments (scFvs) are now emerging as credible alternatives to whole mAbs 
[78]. A scFv is the smallest functional domain of an antibody (~30kDa) comprised of 
only a variable heavy chain and a variable light chain connected by a peptide linker. The 
linker is composed of hydrophilic residues using stretches of glycine and serine 
sequences (Gly4Ser)3, the most common linker sequence for scFv, to make the linker 
flexible [79-81]. Antibody fragments have several advantages over full-bodied mAbs 
including: (i) the fragments are able to penetrate tissues and tumors more rapidly and 
deeply than mAbs due to their size [82-84]; (ii) they are relatively small, unglycosylated 
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proteins allowing them to be produced in microbial expression systems (cheaper and 
quicker than mammalian cultures) [78, 85] while maintaining the targeting specificity of 
a mAb; (iii) they lack the Fc region of the full mAb resulting in a low immunogenicity; 
and (iv) the fragments can be bound to other fragments or fused with a range of 
molecules to produce new, unique molecules for therapeutic applications [78]. However 
there are several disadvantages to antibody fragments: (i) fragments have short half-lives 
in humans causing insufficient accumulation at the target site, making them undesirable 
for therapeutic applications [86-88]; (ii) they are cleared out of humans during kidney 
clearance because the fragments lack a neonatal Fc receptor-mediated recycling found 
on full-length mAbs [89, 90]; and (iii) fragments are less stable than full mAbs and are 
more likely to form undesirable aggregates [91]. 
The scFv used in this study was designed by our collaborator from University of 
California at San Diego to recognize the CD22 antigen from B-cells leukemia and 
lymphomas. The αCD22scFv fragment was produced in the chloroplast of C. reinhardtii 
at   relatively low titers in the order of 0.1 % of total soluble protein.  To purify 
recombinant proteins expressed in microalgae FLAG-tagged recombinant proteins relied 
exclusively on immunoaffinity batch adsorption [71].  
 
3.2.2 Purification of scFv  
Downstream processing is a critical part for the development of commercially 
feasible protein products such as scFvs; a successful process should be able to efficiently 
(high purity and high yield) purify the target product while maintaining low operation 
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costs. A typical purification process is comprised of three stages: (1) primary recovery 
step, (2) capture step, and (3) polishing step. Because the constant Fc region is missing 
in scFvs, traditional purification methods (Protein A or G) monoclonal antibodies cannot 
be applied.  
Natural binding ligands and tag ligands are two affinity-based chromatography 
methods that have been developed to specifically capture and purify scFvs. 
Peptostreptococcal Protein L (PpL) has been  used to purify scFvs due to its high affinity 
to mammalian κ-light chains on the Fab portion of antibodies [92, 93].  About five years 
ago, a commercial chromatography resin with Protein L ligand has been made available 
to ease the purification of antibodies lacking Fc domains. However, not all mammalian 
immunoglobulins have a high affinity to Protein-L based resin [94]. The scFv 
investigated in this study has a mouse κ-light chain; which has a weak affinity to 
Protein-L resins. Short polypeptide sequences or whole proteins co-expressed as fusion 
partners with the target protein can be used to facilitate affinity tag chromatography [95]. 
Currently, immobilized metal affinity chromatography (IMAC) is one of the most 
utilized methodologies to purify scFvs [96, 97] by attaching  a stretch of 6 histidines to  
N or C terminus of  expressed  recombinant fragment. Several labs have reported >90% 
purity by binding scFv-His6 to IMAC [96, 98, 99] after being secreted into the culture 
media. IMAC has several distinct advantages over other affinity systems related to large-
scale purification: low cost, high protein loading, ligand stability, mild elution 
conditions, and easy regeneration [100]. However, lower final purity has been achieved  
with  IMAC compared to PpL-based chromatography [101]. Other disadvantages of 
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IMAC include: need to control the oxidative and reduction conditions inside the column, 
potential metal-induced cleavage of protein backbone, and toxicity of metal ions 
leaching from the solid support. Another tag developed to facilitate affinity purification 
was designed by the RPAS® Purification Module from Amersham Biosciences. They 
used an Anti-E-Tag monoclonal antibody to recognize a 13 amino acid peptide tag (E-
Tag) fused to the C-terminal of a scFv produced from E. coli [102]. When designing 
downstream purification processes that utilize tag affinity chromatography, it is 
important to consider the additional steps needed to remove the tag from the protein, 
which could lead to a more complicated process. A FLAG tag, which consists of 9 
amino acids, was fused to the N-terminus of the scFv analyzed in this study. Anti-
FLAG® M2 Affinity Gel was developed by Sigma-Aldrich for the rapid purification of 
FLAG fusion proteins and was the resin used for rapid purification and detection of the 
target protein [34].  
Even though affinity-based chromatography is the most frequently used 
methodology for first capture of scFvs, other chromatographic methods (ion exchange, 
size exclusion, and hydrophobic interaction) can also be used to purify antibody 
fragments. Several research groups have reported purifications of scFv using only non-
affinity-based chromatographic methods. However, the fragment had either been 
secreted into the culture medium [103, 104] or previously purified using affinity-based 
chromatography [105]. To our knowledge, there is no reported data of using only non-
affinity-based chromatographic methods to purify scFvs from cell lysates.  
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Mixed-mode chromatography has made a large impact on the purification of 
several recombinant proteins from various expression systems. Usually two or more of 
the following types of interactions have  been combined to create a chromatography 
resin with unique selectivity: anion exchange, cation exchange, hydrophobic interaction, 
hydrophilic interaction, hydrogen bonding, pi-pi bonding, and metal affinity [106]. 
Current downstream processes often consist of two to three major separation steps by 
combining multiple purification steps into one, the overall cost of purification could 
drastically decrease. Even though mixed-mode chromatography can have high 
selectivity towards the desired product, method development is complicated and 
unpredictable. One mixed-mode chromatography is hydroxyapatite affinity 
chromatography (HAC), which is used for polishing purification of antibodies, from 
partially purified preparations. HAC combines two modes of interaction: metal affinity 
of protein carboxyl clusters for crystal atoms and cation exchange of positively charged 
protein amino residues with negatively charged crystal phosphates [106].  
 
3.2.3 Purification of scFv from algae  
To establish the feasibility of microalgae as a platform for recombinant protein 
production one has to demonstrate that target protein can be isolated and purified 
without relying on affinity resins. There are only few examples of   purification of 
recombinant proteins produced in the chloroplast of C. reinhardtii and those rely on 
FLAG affinity tags [3-5] for ease of purification and detection. However, using anti-
FLAG-affinity resin to purify recombinant proteins from clarified lysate is not a scalable 
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solution for several reasons: (i) the resin cannot handle high pressures necessitating the 
lysate to be loaded onto the column at unacceptably low flow rates (low productivity); 
(ii) the resin is extremely expensive; and (iii) the binding capacity of the resin is only 
0.6mg/mL requiring a large bed volume. For these reasons, anti-FLAG-affinity resin 
seems   more suitable as an analytical tool and batch purification method for FLAG-
tagged proteins from cell lysates. Thus, one of the objectives of the study was to 
determine if FLAG-affinity could be employed as a polishing step after an anion 
exchange capture chromatography step. 
 
3.3 Materials and methods 
3.3.1 Gene construct for αCD22scFv 
In the construct, the endogenous psbA locus was replaced by αCD22scFv via 
direct homologous recombination. Thus, transgene expression in these strains is 
regulated by the psbA promoter and the 5‟ and 3‟ untranslated regions (UTRs) and, 
therefore, is light inducible. A kanamycin resistance cassette was incorporated for 
selection. The variable domains of a human antibody against the B-cell surface antigen 
CD22 were separated by a linker sequence coding consisting of four glycines and a 
serine repeated four times, (Gly4Ser)4, to create an scFv [3]. The gene cassettes 
(αCD22scFv) was ligated with a sequence coding for a 1× Flag peptide 
(DYKDDDDKS) and separated by a sequence that encodes a Tobacco etch virus (TEV) 
protease cleavage site (ENLYFQG) [3]. 
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3.3.2 Cultivation of αCD22scFv Chlamydomonas reinhardtii strains 
Algal biomass from a single agar plate (Tris-Acetate-Phosphate (TAP) agar with 
150 μg/mL kanamycin) was transferred to 100 mL of TAP media without kanamycin 
and grown for 3 days. A subsequent volumetric culture scale up was performed using 
10% inoculum in the exponential phase (100 mL) in 1 L of fresh TAP media containing 
25 μg/mL kanamycin. One-liter cultures were grown heterotrophically for 5 days, 
reaching ~4 to 5 × 10
6
 cells/mL. The cultures were then exposed to light for 24 hours 
consecutively at a photon irradiance of 101 µmol m
-2
 s
-1
 to induce recombinant protein 
synthesis.  
 
3.3.3 Protein Extraction 
At the end of the light exposure period, cells were harvested by centrifugation at 
3,000 rpm for 5 min at 4ºC. Pelleted algal biomass was washed with fresh TAP media, 
weighted, and then resuspended at 1:5 biomass-to-lysis buffer ratio 50 mM Tris-HCl, 
400 mM NaCl, and 0.5% Tween 20, pH 8.0. The buffer contained a complete protease 
inhibitor cocktail (Roche-Mannheim, Germany) dissolved in 200 mL of the buffer. Algal 
cells were lysed  by sonication for 10 min with 30 seconds on/off intervals at 4°C using 
sonicator (Sonifier 250, Branson, USA) at 30% output control and 30% duty cycle with 
a micro probe (1/8‟ microtip A3-561 Branson, USA). Cell lysates were centrifuged 
(10,000 rpm for 20 min) to produce cell-free extracts. 
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3.3.4 Pretreatment of cell free lysates 
The three pretreatment methods (polymer precipitation, isoelectric precipitation, 
and ammonium sulfate precipitation) were performed on lysates free of cell debris. After 
cell disruption by sonication, the cell debris was removed by centrifugation at 10,000 
rpm for 20 minutes and then by filtration using polyethersulfone (PES) 0.45µm syringe 
filters. 
Polymer precipitation was performed using a stock solution of 10 mg/mL 
chitosan in 1% acetic acid solution (Sigma Aldrich Company, USA). For every gram of 
biomass purified, 30 mg of chitosan was added to the clarified lysate and quickly 
vortexed for 30 seconds to mix the polymer and lysate. The pH of the lysate was 
adjusted to pH 5.0 using 0.2M HCl, mixed end-over-end for 30 minutes at room 
temperature, and centrifuged for 20 minutes at 10,000 rpm. The formed pellet consisted 
of precipitated chitosan and chitosan bound proteins from the lysate. The supernatant 
from the pellet was readjusted to pH 8.0 using 1N sodium hydroxide (NaOH). The lysate 
was centrifuged again at 10,000 rpm for 20 minutes and filtered using a PES 0.45µm 
syringe filter. 
Isoelectric precipitation was accomplished by adding 0.2M HCl drop wise to the 
cell free lysate until the pH of the mixture reached 4.5. The lysate was mixed end-over-
end at room temperature for 15 minutes and then centrifuged for 20 minutes at 10,000 
rpm. The pH of the supernatant was readjusted to 8.0 using 1N NaOH and filtered using 
a PES 0.45µm syringe filter. 
 62 
 
Ammonium sulfate (Sigma Aldrich Company, USA) precipitation was performed 
by adding a stock solution of 3.6 M ammonium sulfate to the cell free lysate until the 
final concentration of ammonium sulfate in solution reached 1.0M and 1.5M (31% and 
53% saturation, respectively). Agitation was provided by end-over-end mixing for 30 
minutes at room temperature, centrifuged at 10,000 rpm for 20 minutes, and filtered 
through a PES 0.45µm syringe filter.  
 
3.3.5 Anion exchange chromatography (AXC) 
To ensure αCD22scFv would bind to the anion exchange column (CaptoTM Q 
(Sigma Aldrich, St. Louis, MO, USA)) before and after pretreatment, the clarified lysate 
was dialyzed against 50mM Tris-Base pH 8.0 to reduce the conductivity of the lysate to 
below 4 mS. The lysate was added to SnakeSkin
®
 Dialysis Tubing 3,500 MWCO 
(Thermo Scientific, Meridian Rd., Rockford, IL, USA) and left in the exchange buffer 
for 24 hours in a 4˚C cold room. A stir bar was added to the buffer to facilitate buffer 
exchange. Conductivity of dialyzed sample was measured by a conductivity meter 
(Model 2052, VWR, Pennsylvania, USA) to ensure low conductivity. After dialysis, 
Capto Q resin was incubated with the lysate for 30 minutes on an end-over-end rotor at 
room temperature. Similar to FLAG-affinity purification, the lysate was placed in a 
centrifuge for 5 minutes at 3,000 rpm to settle the resin. The resin was loaded onto a Bio 
Spin disposable chromatography column (Bio Rad, Hercules, CA, USA), washed with 
10 CVs of washing buffer (50mM Tris-Base, pH 8.0), and eluted step-wise with washing 
buffer plus increasing amounts of salt (0.2, 0.4, 0.6, 0.8, 1.0M NaCl). Two CVs of 
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elution buffer was used before moving to the next elution buffer of additional NaCl. 
Supernatants at the end of the batch adsorption period, washes, and elutions were 
analyzed by western blotting to evaluate adsorption and specific binding to the resin. 
 
3.3.6 Hydrophobic interaction chromatography (HIC) 
Stock solution of 3.6M ammonium sulfate (Sigma Aldrich Company, USA) was 
added to clarified lysate to a final concentration of 1 M ammonium sulfate. The lysate 
was incubated with Phenyl Sepharose
TM
 6 Fast Flow (high sub) (Sigma Aldrich, St. 
Louis, MO, USA) resin on an end-over-end rotor at room temperature for 30 minutes. 
After incubation, the resin was centrifuged for 5 minutes at 3,000 rpm to settle the resin 
and then transferred to a Bio Spin disposable chromatography column (Bio Rad, 
Hercules, CA, USA). The resin was then washed with 10 CVs of washing buffer (50mM 
Tris-Base, 1 M ammonium sulfate, pH 8.0) and eluted using washing buffer plus 
decreasing amounts of ammonium sulfate (0.8, 0.6, 0.4, 0.2, 0M ammonium sulfate). 
Two CVs of elution buffer was used before moving to the next elution buffer of less 
ammonium sulfate. Supernatants at the end of the batch adsorption period, washes, and 
elutions were analyzed by western blotting to assess adsorption and specific binding to 
the resin.  
A final concentration of 1.5M ammonium sulfate in the clarified lysate was also 
tested to increase the adsorption and specific binding to Phenyl Sepharose resin. 
Methodology was similar to 1 M ammonium sulfate except after incubation with resin; 
the washing buffer was 50mM Tris-base, pH 8.0 in 1.5M ammonium sulfate. The 
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recombinant protein was eluted from the resin using the washing buffer with decreasing 
amounts of ammonium sulfate (1.2, 1.0, 0.8, 0.6, 0.4, 0.2, 0M ammonium sulfate). Two 
CVs of elution buffer was used before moving to the next elution buffer of less 
ammonium sulfate. Supernatants at the end of the batch adsorption period, washes, and 
elutions were analyzed by western blotting to gauge increased adsorption and specific 
binding to the resin. 
When HIC was tested as a possible orthogonal purification step after isoelectric 
precipitation and AXC, the elutions from AXC were pooled together and 3.6M 
ammonium sulfate was added to the pool elution to a final concentration of 1.5M 
ammonium sulfate. The pool elution were then mixed end-over-end for 30 minutes at 
room temperature and centrifuged for 20 minutes at 10,000 rpm. Phenyl Sepharose
TM
 6 
Fast Flow (high sub) (Sigma Aldrich, St. Louis, MO, USA) resin was incubated with the 
clarified partially purified sample for 30 minutes at room temperature. After incubation, 
the resin was settled by centrifugation at 3,000 rpm for 5 minutes then transferred into a 
Bio Spin disposable chromatography column (Bio Rad, Hercules, CA, USA). The resin 
was washed with 10 CVs of 50mM Tris-Base, 1.5M ammonium sulfate, pH 5.0. Protein 
was eluted off the HIC washing buffer plus decreasing amounts of ammonium sulfate 
(1.2, 1.0, 0.8, 0.6, 0.4, 0.2, 0M ammonium sulfate). Two CVs of elution buffer was used 
before moving to the next elution buffer of less ammonium sulfate. Supernatants at the 
end of the batch adsorption period, washes, and elutions were analyzed by western 
blotting to assess adsorption and specific binding to the resin. 
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3.3.7 Mixed-mode chromatography 
Macro-Prep Ceramic Hydroxyapatite (HAP) TYPE I 80 µm is a mixed-mode 
chromatography resin. HAP chromatography was tested as a possible orthogonal 
purification step after isoelectric precipitation and AXC. Pooled elutions after AXC were 
added to SnakeSkin
®
 Dialysis Tubing 3,500 MWCO (Thermo Scientific, Meridian Rd., 
Rockford, IL, USA) and left in the exchange buffer (5mM sodium phosphate, pH 6.8) 
for 24 hours in a 4˚C cold room. The partially purified sample was incubated with HAC 
resin for 1 hour at room temperature on an end-over-end rotor. After incubation, the 
resin was settled by centrifugation at 3,000 rpm for 5 minutes then transferred into a Bio 
Spin disposable chromatography column (Bio Rad, Hercules, CA, USA). The resin was 
washed with 10 CVs of 5mM sodium phosphate, pH 6.8 buffer and eluted with 2 CVs of 
200mM sodium phosphate, pH 6.8 followed by 2 CVs of 500mM sodium phosphate, pH 
6.8. Supernatants at the end of the batch adsorption period, washes, and elutions were 
analyzed by western blotting to assess adsorption and specific binding to the resin. 
 
3.3.8 Anti-FLAG-affinity purification 
Partially purified αCD22scFv samples were mixed with anti-FLAG affinity resin 
(Sigma Aldrich, St. Louis, MO, USA); approximately 1 mL of resin was used for every 
20mL of sample. Binding of the recombinant protein to the affinity resin was performed 
for 2 hours at 4 °C by continuous end-over-end mixing in a Glas-Col rotor (Glas-Col 
LLC, Terre Haute, IN, USA) at ~33 rpm (40% speed control). The resin was settled by 
centrifugation at 3,000 rpm for 5 minutes. Affinity resin was transferred into Bio Spin 
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disposable chromatography columns (Bio Rad, Hercules, CA, USA) and washed with 10 
column volumes (CV) of buffer respective to buffer sample is in. Recombinant protein 
was eluted at pH 3.5 using 5 CV of 100 mM glycine buffer, pH 3.5, containing 400 mM 
NaCl. Eluted protein fractions were collected in 5 tubes containing a predetermined 
amount of 1M Tris-HCl, pH 8.0, to immediately neutralize the pH of the eluted protein 
and avoid protein degredation. Typically, three elution fractions (E2 to E4) were used for 
the estimation of purity and yield, although some losses occurred by not taking into 
account E1 (Elution Fraction 1). By pooling these three fractions, more than 80% of 
extracted FLAG-tagged proteins were recovered. Extraction buffer and all of the 
materials used, including the sonication probe (1/8” microtip A3-561 Branson, Danbury, 
CT, USA), were cooled before use. 
The FLAG affinity purification method was used as a convenient analytical tool 
to determine the recombinant yield after pretreatment/capture chromatography methods 
and orthogonal purification steps. The resin was added in sufficient amounts to bind all 
available FLAG fusion protein present in clarified extracts. Supernatants at the end of 
the batch adsorption period were regularly analyzed by western blotting to assure 
complete adsorption and specific binding to the resin. Although minor recombinant 
protein losses have occurred during resin washing and pH 3.5 elution from the anti-
FLAG resin, this determination of recombinant protein concentration was considered 
appropriate for estimating recombinant protein in crude extracts. 
Column purification of AEX pool by FLAG-affinity resin was performed with a 
12 mL column (1.6×6 cm). Twelve milliliters of AEX pool were loaded at 0.1 mL/min 
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(3 cm/h). The column was then washed with 5 CVs of 50mM Tris, pH 8.0 followed by 6 
CVs of 100 mM glycine buffer, pH 3.5, containing 400 mM NaCl. Resulting peaks 
separated by the affinity column were analyzed by SDS-PAGE and western blotting. 
 
3.3.9 Protein Analysis 
Total soluble protein in clarified lysate and purified fractions were analyzed 
using the Bradford assay with a working range from 25 to 1500 µg/mL. The samples 
were quantified using Coomassie Plus assay kit (Thermo Scientific, Waltham, MA, 
USA) measured using VERSA max plate reader (Molecular Devices, Sunnyvale, CA, 
USA) at wavelength 595 nm.  
Supernatants and purified fractions were also analyzed using SDS-PAGE and 
Western Blots; all gels, stains, membranes, and chemicals were acquired from 
Invitrogen™ (Carlsbad, CA, USA). Samples were prepared with a reducing buffer 
(composed of NuPAGE LDS Sample Buffer 4x and 10% 2-marcaptoethanol), 
thoroughly mixed, and placed on a heating block, set at 70˚C, for 10 minutes. After 
cooling, the samples were loaded onto a NuPAGE® Novex® Bis-Tris pre-packed 
gradient gel (1.5mm x 10 wells). A running buffer (1X MES SDS Running Buffer) was 
used to carry the current and create a uniform electric field on the gel. Antioxident was 
also present in the running buffer to ensure proteins would remain in their linear form 
during electrophoresis. The system ran for 35 minutes at a constant voltage of 200V. The 
gels were then blocked with a 10% acetic acid, 40% ethanol, 50% reverse osmosis (RO) 
water fixing solution for 45 minutes to prevent diffusion of proteins, ensuring sharp and 
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resolved bands during the staining process. The fixing solution was rinsed off the gel and 
stained using CoomassieTM G-250 stain for 3 hours. Pictures of the stained gels were 
taken using a Gel Logic 100 Imaging System.  
For Western blot analysis, the samples were run on a NuPAGE® Novex® Bis-
Tris pre-packed gradient gel (1.5mm x 10 wells) in the same manner as SDS-PAGE. 
However, after running the gel, it was transferred to a nitrocellulose membrane using 
iBlot® 7-Minute Blotting System. After protein transfer, the membrane was blocked 
with 2.5% non-fat milk in a solution of Tris-Buffered Saline and Tween 20 (TBS-T) for 
1 hour to prevent non-specific binding of the antibody. The membrane was washed three 
times with TBS-T then incubated with anti-FLAG M2 AP for one hour. The antibody 
was at a concentration of 1:2000 for detection of anti-FLAG-tagged αCD22scFv. The 
membrane was washed again three times with TBS-T to remove any remaining antibody 
that did not bind to FLAG-tagged proteins. Nitro-blue tetrazolium (NBT) and 5-bromo-
4-chloro-3’-indolyphosphate p-toluidine salt (BCIP) dissolved in 10 mL of ROW was 
used to develop the membrane. Gel Logic 100 Imaging System was used to take pictures 
of the developed membrane. 
 
3.4 Results and discussion 
3.4.1 Stability of αCD22scFv during adsorption to Capto Q resin  
During large scale purification of protein therapeutics, depending on how quickly 
the clarified extract can be processed, the target protein could be exposed to potential 
proteolytic activities present in clarified extracts for several hours. Before proceeding 
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with the investigation of alternative non-affinity chromatography steps, we wanted to 
demonstrate αCD22scFv remains intact in clarified lysates for a lengthy amount of time 
at room temperature. The typical lysate volume in our experiments to be purified using 
packed column purification was 60mL. The time required for 60 mL of non-pretreated 
lysate to be manually loaded onto a column with a bed volume of 4.7 mL (0.7x10cm) at 
a linear velocity of 50 cm/h was 5 hours. To subsequently wash the column of any non-
specifically bound proteins (mimicking batch purification process, 8 CVs of washing is 
sufficient) would require an additional 2.5 hours. Assuming the proteases were also 
bound to the column and remained on the column with the target protein, we had to 
demonstrate that αCD22scFv would remain intact for 7 hours at room temperature.  
Using batch in determine αCD22scFv stability, clarified lysate was mixed for 7 hours 
with Capto Q at room temperature. The stability of the αCD22scFv fragment during the 
Capto Q adsorption process can be found on the Western blot in Figure 15. Lanes 2-4 
show the initial presence of αCD22scFv at time zero and lanes 5-10 are samples taken 
after 7 hours. There were minor losses of the fragment during adsorption and washing of 
the resin (Lanes 5 and 6), but a majority of αCD22scFv were concentrated in the elution 
fractions (Lanes 7-10). The strong single bands in the elution fractions indicate no 
measurable degradation of αCD22scFv after being bound to Capto Q resin for 7 hours at 
room temperature.  
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Figure 15. Stability of αCD22scFv bound to Capto Q resin in clarified lysate for 7 hours 
at room temperature. Western Blot analysis of αCD22scFv using anti-FLAG-AP 
conjugated antibody. Lane 1: molecular weight marker (kDa); Lane 2: 10X diluted 
supernatant after sonication of cells; Lane 3: 10X diluted supernatant after filtration 
through PES 0.22µm syringe filter; Lane 4: 10X diluted supernatant after dialysis; Lane 
5: 10X diluted supernatant after 7 hours binding with anti-FLAG resin; Lane 6: 10X 
diluted washes before elution; Lane 7-10: 50mM Tris-base, 1M NaCl pH 8.0 eluted 
fractions. 
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3.4.2 Comparing effect of pretreatment methods with αCD22scFv adsorption to Capto Q 
and Phenyl Sepharose resin 
Our lab [34] previously analyzed the effects of three pretreatment methods 
(ammonium sulfate precipitation at pH 8.0, isoelectric precipitation at pH 4.5, and 
chitosan precipitation at pH 5.0) on residual chlorophyll, DNA, host cell protein, and 
αCD22scFv yield (Table 2). Isoelectric precipitation was determined to be the ideal 
pretreatment method, with ammonium sulfate a close second choice, for significantly 
reducing the amount of chlorophyll and host cell protein, while maintaining a high 
αCD22scFv yield. Even though there was a significant loss (35%) in recombinant 
protein after chitosan precipitation, the significant reduction in DNA, host cell protein, 
and chlorophyll prompted us to also evaluate chitosan pretreatment. Batch affinity 
adsorption was used to determine the amount of αCD22scFv left in the supernatant after 
each pretreatment. Because we established that anti-FLAG-affinity resin is not an 
acceptable option for large scale purification. Each of these pretreatments evaluated was 
paired with most compatible non-affinity adsorption. After polymer precipitation and 
isoelectric precipitation, the conductivity of the pretreated sample is relatively low; 
therefore, the next logical step for capture chromatography would be AXC because of 
the acidic pI of αCD22scFv (pI=4.5). Because 1M ammonium sulfate produces a high-
conductivity lysate, the most logical step would be to bind the protein to HIC.  
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Table 2. Effect of pretreatment method stage of implementation on residual DNA, 
chlorophyll, host cell protein, and αCD22scFv yield in algae extract. Values given are 
averages from 3 replicates ± standard deviations. 
a,b,c,d,e
 For each observation that do not 
share a common superscript letter are significantly different from the control no 
pretreatment (P < 0.05). 
 
 
 
Each pretreatment method was performed on the lysate and then incubated with 
its respective resin for 30 minutes at room temperature (uptake experiments in Appendix 
II). After adsorption to the respective resin, the bound protein was then eluted off the 
resin. The supernatants after batch adsorption and washing step for 1M ammonium 
sulfate (Figure 16a), chitosan precipitation (Figure 16b), and isoelectric precipitation 
(Figure 16c) were analyzed by western blotting. Finding αCD22scFv in the supernatant 
after binding and in the wash is undesirable indicating a weak interaction between the 
FLAG-tagged protein and resin under those conditions (i.e. loss of αCD22scFv during 
the purification process). Comparing the three Western blots, it is clear that the 1M 
ammonium sulfate pretreatment resulted in significant αCD22scFv loss in both 
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supernatant and wash fractions (Figure 16a). Chitosan pretreatment affected primarily 
the adsorption of αCD22scFv (Figure 16b). The Western blot in Figure 16c shows that 
isoelectric precipitation at pH 4.5 has the faintest band in the supernatant and washing 
fractions. This indicates that isoelectric precipitation-anion exchange chromatography is 
potentially the best pretreatment-capture step combination because almost all of 
αCD22scFv binds to the resin and the binding is strong enough for the protein to remain 
on the resin after washing. 
 
 
 
Figure 16. (a) 1M ammonium sulfate precipitation Western blot analysis of αCD22scFv 
using anti-FLAG-AP conjugated antibody. Lane 1: supernatant after 30 minutes of 
binding with Phenyl Sepharose resin; Lane 2: wash of Phenyl Sepharose resin after 30 
minutes of incubation with supernatant. (b) Chitosan precipitation Western blot analysis 
of αCD22scFv using anti-FLAG-AP conjugated antibody. Lane 1: supernatant after 30 
minutes of binding with Capto Q resin; Lane 2: wash of Capto Q resin after 30 minutes 
of incubation with supernatant. (c) Isoelectric precipitation at pH 4.5 Western blot 
analysis of αCD22scFv using anti-FLAG-AP conjugated antibody. Lane 1: supernatant 
after 30 minutes of binding with Capto Q resin; Lane 2: wash of Capto Q resin after 30 
minutes of incubation with supernatant. 
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Since isoelectric precipitation-Capto Q was identified as the best pretreatment-
capture step combination, a SDS-PAGE (Figure 17a) and Western blot (Figure 17b) of 
the pretreatment and AXC process was performed to determine αCD22scFv purity after 
the first capture step. The eluted fractions from AXC (Lanes 6-10) strongly reacted on 
the Western blot when probed with anti-FLAG-AP conjugated antibody. Furthermore, 
the elution fractions also have a reduced amount of total soluble protein, compared to the 
clarified lysate (Lane 2), indicating an increased purity of αCD22scFv after the capture 
chromatography step. It is interesting to note that αCD22scFv is detected by Western 
blot in all of the elution fractions (Lanes 6-10), suggesting a rather broad range of pIs for 
CD22scFv. Using anti-FLAG affinity resin to quantify the FLAG-tagged protein 
remaining in solution, it was determined that the AEX step yielded a CD22scFv purity of 
1.7%. With a starting purity of 0.14% TSP, isoelectric precipitation followed by AXC 
provided a 12-fold increase in purity. 
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Figure 17. Purification of αCD22scFv after isoelectric precipitation and AXC. (a) 
Coomassie-stained SDS-PAGE of αCD22scFv.  Lane 1: molecular weight marker (kDa); 
Lane 2: clarified algae extract; Lane 3: supernatant after isoelectric precipitation from 
pH 4.5 to pH 8.0; Lane 4: supernatant after 30 minutes of binding with Capto Q resin at 
room temperature; Lane 5: washing of Capto Q resin before elution; Lane 6-10: elution 
fractions by step-wise elutions with increasing concentrations of salt. (b) Western blot 
analysis of αCD22scFv samples run on SDS-PAGE using anti-FLAG-AP conjugated 
antibody. Black arrow indicates αCD22scFv. 
 
3.4.3 Screening of Phenyl Sepharose and HAP as possible intermediate purification 
steps 
To increase the purity of αCD22scFv, an orthogonal chromatography step needs 
to be implemented. Elution fractions after AXC were pooled together. A final 
concentration of 1.5M ammonium sulfate was added to the pooled elution fractions and 
batch purified with Phenyl Sepharose resin for 30 minutes at room temperature. The 
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elution fractions were run on SDS-PAGE gels to analyze purity of the fractions (Figure 
18). The first two elution fractions (Lanes 1 and 2) show very little protein in solution. 
Total soluble protein increases in the elution fractions as the conductivity of eluent 
decreases, with Lanes 8-10 containing the largest amounts of total protein. Even though 
the total protein detected on the SDS-PAGE increased as the conductivity of the elution 
buffer decreased, the elution of αCD22scFv did not correlate in the same manner 
according to analysis of elutions run on the Western blot (Figure 19). The target protein 
comes off the resin as soon as the elution starts (Lanes 2 and 3). The intensity of the 
bands on the Western blot increases until Lane 5. However, αCD22scFv is still detected 
in Lanes 6-10. Comparing the impurities in the SDS-PAGE to the αCD22scFv response 
in the Western blot, it was determined that the first four elution fractions (Lanes 2-5) 
would provide the highest recombinant protein purity. 
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Figure 18. Purification of αCD22scFv using Phenyl Sepharose resin as intermediate 
purification step after isoelectric precipitation and AXC. Coomassie-stained SDS-PAGE 
of αCD22scFv. Lane 1: molecular weight marker (kDa); Lanes 2-3: 1.2M ammonium 
sulfate elution fractions; Lanes 4-5: 1.0M ammonium sulfate elution fractions; Lanes 6-
7: 0.8M ammonium sulfate elution fractions; Lanes 8-9: 0.6M ammonium sulfate elution 
fractions; Lanes 10-11: 0.4M ammonium sulfate elution fractions; Lanes 12-13: 0.2M 
ammonium sulfate elution fractions; Lanes 14-15: 0M ammonium sulfate elution 
fractions. Black arrow indicates αCD22scFv. 
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Figure 19. Western blot analysis of reduced αCD22scFv using anti-FLAG-AP 
conjugated antibody after elution from Phenyl Sepharose resin as an orthogonal step to 
isoelectric precipitation at pH 4.5 and elution from Capto Q resin. Lane 1: molecular 
weight marker (kDa); Lanes 2-3: 1.2M ammonium sulfate elution fractions; Lanes 4-5: 
1.0M ammonium sulfate elution fractions; Lanes 6-7: 0.8M ammonium sulfate elution 
fractions; Lanes 8-9: 0.6M ammonium sulfate elution fractions; Lane 10: 0.4M 
ammonium sulfate elution fractions. 
 
The selected elution fractions (Lane 2-5) were pooled together and lyophilized to 
remove the water and concentrate all soluble proteins. The lyophilized proteins were 
resuspended in 0.5 mL RO water and run on an SDS-PAGE (Figure 20) to more 
accurately determine the purity of αCD22scFv. The arrow identifies αCD22scFv on the 
gel in comparison to the other proteins also in solution. 
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Figure 20. Coomassie-stained SDS-PAGE of highly concentrated αCD22scFv after HIC 
as orthogonal chromatography step. Lane 1: molecular weight marker (kDa); Lane 2: 
concentrated pooled elution fractions (Lanes 2-5 from Figures 19 and 20). Black arrow 
indicates αCD22scFv. 
 
Based on the concentrated pool, αCD22scFv is about 5% pure; only a 3-fold 
increase in purity from the isoelectric precipitation and anion exchange purification. 
After a pretreatment step and two chromatography steps, a final purity of only 5% is 
unacceptable (a minimum of 10-fold increase in purity is considered acceptable in 
manufacturing). Therefore, a different resin was screened as a possible orthogonal 
chromatography step to increase αCD22scFv purity. 
HAP is a mixed-mode chromatography resin commonly used for polishing 
purification of monoclonal antibodies and was tested as a possible orthogonal step after 
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isoelectric precipitation and AXC. Elution fractions 1-8 (Figure 17, Lanes 6-9) after 
isoelectric precipitation/AXC were pooled together and batch purified using HAP resin 
for 30 minutes at room temperature. Supernatants after batch adsorption, washing 
fractions, and elution fractions were qualitatively analyzed using SDS-PAGE gels 
(Figure 21a) and Western blots (Figure 21b). 
 
 
 
Figure 21. Purification of αCD22scFv using HAP as intermediate purification step after 
isoelectric precipitation and AXC. (a) Coomassie-stained SDS-PAGE of reduced 
αCD22scFv. Lane 1: molecular weight marker (kDa); Lane 2: Pooled elutions from 
Capto Q resin; Lane 3: partially purified sample after buffer exchange into 5mM sodium 
phosphate pH 6.8; Lane 4: supernatant after 30 minutes binding with HAP resin; Lane 5: 
washing HAP resin before elution; Lanes 6-7: 200mM sodium phosphate pH 6.8 
elutions; Lane 8-9: 500mM sodium phosphate pH 6.8 elutions. (b) Western blot analysis 
of αCD22scFv using anti-FLAG-AP conjugated antibody on same samples as SDS-
PAGE. 
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Very little protein is detected by SDS-PAGE in the supernatant after purification 
with HAP and during the washing step. This means that a majority of the soluble 
proteins in the partially purified sample was bound to the resin. Elution fractions with 
200mM sodium phosphate eluent (Lanes 6 and 7) contained a majority of the soluble 
proteins bound to the resin while the elution fractions with 500mM sodium phosphate 
(Lanes 8 and 9) contained the proteins that have the strongest affinity toward HAP resin 
(Figure 21a). Based on previous data, αCD22scFv has shown to elute off the resin 
needing only 200mM sodium phosphate (data not shown). Unfortunately qualitative 
analysis of the Western blot (Figure 21b) shows Lanes 4 and 5 to contain thick, dark 
bands, indicating a substantial amount of αCD22scFv not bound to the resin and washed 
off the resin. The main fractions capturing αCD22scFv (Lanes 6 and 7) also had a large 
concentration of impurities, resulting in a low αCD22scFv yield and purity after the 
orthogonal chromatography step. Therefore, HAP is not a suitable orthogonal 
chromatography step for intermediate purification of αCD22scFv. 
 
3.4.4 Purification of αCD22scFv by Capto Q and FLAG-affinity chromatography 
The bench scale purification process consisting of isoelectric precipitation and 
AXC was scaled up using AktaPurifier. The chromatogram of Capto Q purification of 
pretreated lysate is shown in Figure 22.  
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Figure 22. Chromatogram of Chlamydomonas reinhardtii and pretreated lysate purified 
using AXC Capto Q resin. The chromatogram is plotted with absorbance at 280nm 
(mAU) and conductivity (mS/cm) against time (min).  Sample Injection is marked by 
pink dashed line and each sample collected are labeled at the bottom of the 
chromatogram. 
 
The flow through fractions (soluble protein that did not bind to the column) 
encompassed Fractions A2-A9, column wash fractions A10-A15. The elution gradient 
started at A15. Gradient elution resulted in several distinct peaks. In order to determine 
which peak contains αCD22scFv, samples from selected fractions were run on a Western 
blot (Figure 23a). The same samples were also run on a SDS-PAGE to determine the 
purity (Figure 23b).  
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Figure 23. Analysis of fractions collected by AktaPurifer after binding and elution to 
Capto Q column. (a) Western blot analysis of αCD22scFv using anti-FLAG-AP 
conjugated antibody. Lane 1: molecular weight marker (kDa); Lane 2-10: Fractions 
collected from AktaPurifier. (b) Coomassie-stained SDS-PAGE of same samples on 
Western blot. 
 
The Western blot shows that αCD22scFv eluted in fractions B10-B2 (between 
conductivities 10 and 35 mS/cm) The wide distribution of αCD22scFv can be explained 
by the range of isoelectric points pI 4.5-5 found in αCD22scFv determined by 2-D 
electrophoresis (See Appendix III). The SDS-PAGE showed an initial low concentration 
of soluble proteins but as the conductivity of the eluent increased, so did the 
concentration of impurities. To minimize the loading volume onto anti-FLAG-affinity 
resin, only fractions B10-B5 (Lanes 2-7) were pooled and run on the affinity column. 
The 12mL pooled sample was loaded on a 12mL FLAG affinity column at a linear 
velocity of 3 cm/h and 4°C. The low linear velocity was used to ensure a 2 hour contact 
time of αCD22scFv with the resin. A chromatogram of the FLAG purified sample is 
shown in Figure 24.  
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Figure 24. Chromatogram of partially purified Chlamydomonas reinhardtii αCD22scFv, 
by Capto Q resin, further purified using anti-FLAG affinity resin. The chromatogram is 
plotted with absorbance at 280nm (mAU) against time (min). Injection of sample is 
marked by pink dashed line and fractions collected are noted at the bottom of the 
chromatogram. 
 
Two peaks are shown on the chromatogram, the first coming out mainly in 
fraction D5 and the other is distributed over fractions E6-E14. The first peak contains 
algal proteins that did not bind to the anti-FLAG resin. The second peak was eluted 
during the pH-step change from pH 7.5 to pH 4.4. The fractions under each peak were 
concentrated and run on a Western blot (Figure 25a) and a SDS-PAGE (Figure 25b). 
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Figure 25. (a) Western blot analysis of concentrated αCD22scFv using anti-FLAG-AP 
conjugated antibody. Lane 1: molecular weight marker (kDa); Lane 2: concentrated 
Fraction D5; Lane 3: 2X diluted pooled Fractions E8-E12; Lane 4: 4X diluted pooled 
Fractions E8-E12; Lane 5: 8X diluted pooled Fractions E8-E12; Lane 6: concentrated 
pooled Fractions D13-D14. (b) Coomassie-stained SDS-PAGE of concentrated 
αCD22scFv purified with FLAG affinity chromatography. Lane 1: : molecular weight 
marker (kDa); Lane 2: concentrated Fraction D5; Lane 3: concentrated pooled Fractions 
E8-E12; Lane 4: 2X diluted pooled Fractions E8-E12; Lane 5: concentrated pooled 
Fractions D13-D14. 
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Analysis of the Western blot showed that αCD22scFv was completely bound to 
the FLAG-affinity resin since there was no cross-reaction band in Lane 2 when probed 
with the anti-FLAG-AP conjugated antibody. The pooled elution fractions (Lanes 3-5) 
of the same sample were analyzed at different dilutions to qualitatively compare 
αCD22scFv band thickness to the other bands in the lane. The eluted peak (Lanes 3-5) 
shows multiple bands on the SDS-PAGE, indicating multiple sized proteins are found in 
the sample. However, the same sample run on the Western blot also shows multiple 
bands similar to the bands on the SDS-PAGE. Therefore, the bands on the SDS-PAGE 
are all FLAG-tagged proteins. The eluted peak purified by FLAG-affinity resin contains 
highly purified αCD22scFv (Table 3). 
 
Table 3. Purity and yield of αCD22scFv after each clarification/chromatography step. 
 
Sample Process step  Purity Purification 
fold 
Yield 
Clarified lysate Initial 0.14% 1 100% 
Isoelectric 
precipitation at 
pH 4.5 
Pretreatment 0.4% 2.9 100% 
Anion exchange 
chromatography 
Capture 1.7% 12 78% 
FLAG-affinity 
chromatography 
Polishing  >98% FLAG-
tagged 
proteins 
(~50% 
monomeric 
form) 
700 ~77% (~40% 
monomeric 
form) 
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Pretreatment resulted in a 3-fold enrichment of αCD22scFv and AEX in an 
additional 4-fold enrichment. As expected, significant increase in purification was 
achieved during affinity step, which resulted in 700-fold enhancement. A final 
αCD22scFv yield of 77% and >98% purity are incredibly good results, especially since 
the initial product titer was so low, larger losses in yield could have easily occurred. 
 
3.5 Summary 
Single-chain antibody fragments are becoming a more promising possibility for 
pharmaceutical industries because they can be produced quicker and cheaper than full-
size antibodies while still maintaining the target specificity of whole mAbs. Being only a 
fraction of mAbs (~30kDa), provides the fragments with several advantages such as, 
rapid and deep penetration into tissues and tumors, and numerous therapeutic 
applications when bound or fused to other fragments or molecules. Since scFvs are small 
in size, simple in structure, and non-glycosylated, the chloroplast of eukaryotic 
microalgae C. reinhardtii could be a potential production system for scFvs.  
Our lab previously analyzed the effects of three pretreatment methods (ammonium 
sulfate precipitation at pH 8.0, isoelectric precipitation at pH 4.5, and chitosan 
precipitation at pH 5.0) on residual chlorophyll, DNA, host cell protein, and αCD22scFv 
yield. Isoelectric precipitation was determined to be the ideal pretreatment method, with 
ammonium sulfate a close second choice. Both methods significantly reduced the 
amount of chlorophyll and host cell protein, while maintaining a high αCD22scFv yield. 
Even though the pretreatment methods have been shown to benefit protein recovery, no 
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previous research has been done with algal extracts to show their effects on downstream 
processesing. Therefore, this study tested the effect of the pretreatment methods on 
purification of αCD22scFv using the two commercial resins, Phenyl Sepharose and 
Capto Q.  
At 1M ammonium sulfate, a large percentage of the target protein came off the 
resin during the wash; indicating that the hydrophobicity of αCD22scFv at 1M 
ammonium sulfate was not strong enough to bind to the resin. Using 1M ammonium 
sulfate as a pretreatment method before capture chromatography provides little to no 
effect on downstream processing, it only increases the final production cost. However, 
chitosan and isoelectric precipitation yielded the same final purity. Unfortunately, anion 
exchange chromatography could not capture all of the target protein after chitosan 
precipitation and some of the target protein was non-specifically bound to the resin and 
came out in the wash. Therefore, it was concluded that the isoelectric precipitation-anion 
exchange chromatography combination was the best for initial recovery and 
concentration of αCD22scFv.  
After the AEX capture step αCD22scFv was 1.7%, a 4-fold increase from 
precipitation step in purity which is a reasonable increase for a capture step. To increase 
the final purity an orthogonal chromatography step was implemented using Phenyl 
Sepharose resin using a final concentration of 1.5M ammonium sulfate. Even with the 
increased concentration of ammonium sulfate, not all of αCD22scFv bound to the HIC 
resin and still some of the target protein was non-specifically bound to the column and 
came off during the wash. The final purity of the cleanest elution fractions was only 5%, 
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an unacceptable purity after a pretreatment method and 2 chromatography steps. A 
second attempt of scouting an orthogonal chromatography step to further purify 
αCD22scFv was made by using HAP resin. Not only did HAP fail to completely take up 
αCD22scFv from the partially purified solution, a bit larger proportion of the protein 
came off the column during the washing step before elution. Also, αCD22scFv eluted off 
the column with other impurities, resulting in a poor yield. Therefore, no viable 
orthogonal non-affinity chromatographic step was identified.  
The batch purification process of isoelectric precipitation, AXC, and FLAG-
affinity chromatography was scaled up using AktaPurifier. By pooling and running the 
partially purified elution fractions through a FLAG-affinity column, yielded highly 
purified αCD22scFv (>98% purity). 
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CHAPTER IV 
CONCLUSIONS AND RECOMMENTATIONS 
 
4.1 Conclusions 
The chloroplast of eukaryotic green algae has shown its ability to produce 
correctly folded complex recombinant proteins. This study attempted to better 
understand downstream processing of acidic proteins in algal lysate. The research 
increased the current scientific knowledge on the viability of microalgae as possible 
commercial platforms for recombinant proteins. The major challenges identified in this 
study were: (i) extremely low transgene expression levels, (ii) broad range of charge 
variances of target proteins, and (iii) trouble separating the acidic recombinant protein 
from impurities, mainly rubisco, which is almost identical to the recombinant protein in 
size and charge. 
Our collaborators, Mayfield’s laboratory in San Diego, California, proved that a 
malaria transmission blocking vaccine (TBV), Pfs25, and a single-chained antibody, 
αCD22scFv, were correctly produced in the chloroplast of Chlamydomonas reinhardtii. 
Gregory reported that affinity-purified Pfs25 was cross-reacting with anti-Pfs25-mAb 
4B7 at a 4×higher molecular weight than expected. Pfs25 has shown success of high 
immunogenicity in humans and transmission blocking activity when produced in other 
expression systems (like yeast and tobacco). However, to further drive down the cost of 
production, algae is an excellent potential candidate for cheaply made Pfs25. Therefore, 
Chapter II of this research is dedicated to increasing the accumulation of Pfs25 in the 
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chloroplast of C. reinhardtii and to characterize the size and stability of higher molecular 
weight Pfs25 proteins reported by Gregory and Vinetz. By suspending algal cells in 
fresh media after 5 days of growth, 24 hours before exposure to light, the accumulation 
of Pfs25 increased 1.7-fold. The affinity-purified Pfs25 was separated on a size 
exclusion column (SEC) and, based off the calibration curve of the column, the size of 
the aggregates ranged in size from 25 kDa to >600 kDa. The aggregates were found to 
remain intact even in the presence of reducing agents and detergent. Another concern of 
ours was that the aggregates were being formed during the low pH elution step during 
affinity-purification. Therefore, FLAG-peptide was used to desorb Pfs25 from the 
column at neutral pH. The eluted protein was separated on the SEC and even though the 
profile of the chromatogram was different, high molecular weight proteins >600 kDa 
were still found in the FLAG-peptide eluted Pfs25 sample. The Pfs25 complexes were 
not exclusively formed during the low pH elution step. Previous research on Pfs25 (no 
matter the expression system) has shown that Pfs25 in its monomeric form does not 
induce an immunogenic response. Therefore, researchers must either chemically 
conjugate Pfs25 to itself or other proteins or combine it with an adjuvant. Algae, since 
Pfs25 has shown it naturally forms complexes of itself, could have the potential of 
inducing an immunogenic. Therefore, the immunogenicity of Pfs25 complexes should be 
studied to further understand the viability of using microalgae as a possible production 
platform for recombinant proteins. 
Previously our lab studied different process variables affecting extraction and 
recovery of recombinant protein in algal lysate. It was determined that out of three 
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pretreatment options studied (chitosan precipitation, ammonium sulfate precipitation, 
and isoelectric precipitation), ammonium sulfate and isoelectric precipitation 
significantly reduced residual chlorophyll and host cell proteins while recovering a large 
portion of αCD22scFv. The pretreatment options were compared using anti-FLAG-
affinity resin as a quantitative method. Unfortunately, FLAG-affinity resin is not a 
practical resin for commercial use due to it being extremely expensive, has a low binding 
capacity, and is easily compressible. Therefore, in Chapter III of this research, compares 
the three pretreatment methods on its effects on αCD22scFv adsorption to non-affinity 
commercial resins, Capto Q and Phenyl Sepharose. It was determined that isoelectric 
precipitation at pH 4.5 and anion exchange chromatography combination was the best 
for initial recovery and concentration of αCD22scFv, resulting in a 12-fold increase in 
purity of αCD22scFv. Hydroxyapatite resin and Phenyl Sepharose resin were then 
scouted to further increase the purity of αCD22scFv; unfortunately no viable orthogonal 
non-affinity chromatographic step was identified. Using FLAG-affinity resin after 
isoelectric precipitation and AXC resulted in a purity of αCD22scFv >98% and a 77% 
yield. 
 
4.2 Recommendations 
The suggestions for future work include: 
1. Increase the expression level of both Pfs25 and αCD22scFv. 
2. Study the immunogenic response of Pfs25 complexes in mice. 
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3. To screen more resins as possible intermediate purification chromatography 
steps, to hopefully remove affinity chromatography entirely from the purification 
process. 
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APPENDIX 
 
Appendix I Chromatogram of FLAG-purified Pfs25 separated by QA monolithic 
disk. 
The 2-D electrophoresis gel (Figure 8) revealed that purified Pfs25 has several 
charge variants, the same characteristic was assumed to hold true with aggregates 
comprised of Pfs25 as well. Therefore, purified Pfs25 was run on a QA monolithic disk 
to try to separate the monomeric forms of Pfs25 from its multimeric forms. Figure 26 is 
the chromatogram of purified Pfs25 bound and desorbed from the QA monolithic disk. 
Unfortunately, baseline separation was not achieved between the eluted peaks; therefore, 
the QA monolithic disk was not an effective method to separate the different aggregates 
of Pfs25.  
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Figure 26. Chromatogram of FLAG-purified Pfs25 separated by QA monolithic disk. 
 
Appendix II Uptake experiments to determine possibility for binding to Capto Q 
and Phenyl Sepharose resin 
During a continuous purification process, for a column with a bed volume of 4.7 
mL (0.7x10cm) at a linear velocity of 50 cm/h, αCD22scFv has a retention time of 20 
minutes to bind to the column before the solution has traveled out of the column. Non-
pretreated lysate was batch purified with Capto Q resin for 5, 15, 30, and 60 minutes to 
determine the minimum amount of time needed for maximum amount αCD22scFv to 
bind to the resin. The supernatant of the lysate after incubation with Capto Q resin at 
each time point was run on a Western Blot to determine how much αCD22scFv 
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remained in the solution. The supernatant after binding to the resin after 5 minutes 
(Figure 27, Lane 5) had a relatively darker band on the Western blot than the 
supernatants at the other incubation time points (Lanes 6-8) indicating a greater amount 
of FLAG-tagged protein did not adsorb to the resin after 5 minutes of uptake. The 
supernatants after time points 15, 30, and 60 minutes seem to have the same band 
thickness of FLAG-tagged recombinant protein; approximately the same amount of 
αCD22scFv is left in the supernatants. This qualitative analysis suggests that 15 minutes 
of incubation with the Capto Q resin is the minimum amount of time for maximum 
protein binding to the resin; increased incubation time will not increase the amount of 
αCD22scFv bound to the resin. To ensure consistency in subsequent batch experiments, 
30 minutes was used as the incubation time of pretreated lysate and Capto Q resin. This 
experiment also serves as a baseline to test the efficiency of pretreatment methods and 
its ability to reduce the amount of impurities in solution and increase the interaction 
between αCD22scFv and the resin. 
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Figure 27. Uptake experiment with Capto Q resin. Western Blot of αCD22scFv using 
anti-FLAG-AP conjugated antibody. Lane 1: molecular weight marker (kDa); Lane 2: 
10X diluted supernatant after centrifugation; Lane 3: 10X diluted supernatant after 
filtration through PES 0.22µm syringe filter; Lane 4: 10X diluted supernatant after 
dialysis; Lane 5: 10X diluted supernatant after 5 minutes of binding with Capto Q resin; 
Lane 6: 10X diluted supernatant after 15 minutes of binding with Capto Q resin; Lane 7: 
10X diluted supernatant after 30 minutes of binding with Capto Q resin; Lane 8: 10X 
diluted supernatant after 60 minutes of binding with Capto Q resin. 
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Another non-affinity commercial resin being tested as a capture chromatography 
step is hydrophobic interaction resin, Phenyl Sepharose. A similar experiment to the 
anion exchange purification was performed on the hydrophobic interaction resin. 
However, instead of removing the conductivity in the lysate by dialysis, the conductivity 
of the lysate increased by adding ammonium sulfate to a final concentration of 1M 
ammonium sulfate. Batch binding purification was performed on the clarified lysate with 
1M ammonium sulfate and Phenyl Sepharose resin for 5, 15, 30, and 60 minutes to 
determine how much time is needed for αCD22scFv to completely bind to the resin. 
Samples of the supernatant after the time points and the first column volumes of wash 
were analyzed by western blotting to determine affinity and specificity of αCD22scFv to 
Phenyl Sepharose resin. Elution fractions after 60 minutes of binding time were also 
analyzed by western blotting (Figure 28).  
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Figure 28. Uptake experiment with 1M ammonium sulfate and Phenyl Sepharose resin. 
Western Blot using anti-FLAG-AP conjugated antibody to detect αCD22scFv. Lane 1: 
molecular weight marker (kDa); Lane 2: supernatant  after centrifugation; Lane 3: 
supernatant of clarified lysate; Lane 4: supernatant after 1M ammonium sulfate 
precipitation; Lanes 5, 7, 9, and 11: supernatant after mixing with Phenyl Sepharose 
resin for 5, 15, 30, and 60 minutes; Lanes 6, 8, 10, and 12: 1
st
 and 2
nd
 CVs of washing 
column before elution; Lanes 13-17: elution fractions of resin mixed with clarified lysate 
for 60 minutes at room temperature. 
 
Strong bands are seen on the Western blot in the lanes containing supernatant 
after protein uptake to Phenyl Sepharose resin and washing fractions. However, no 
reaction took place on the membrane in Lanes 13-17 when probed with anti-FLAG-AP 
conjugated antibody (no FLAG-tagged proteins came off the column during the low 
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conductivity elution). This indicates that αCD22scFv was unable to adsorb to the resin 
under current binding conditions. Enough resin was available during the residence 
period; hence there was plenty of binding sites for αCD22scFv to bind to the resin. 
Therefore the only way to increase the binding to Phenyl Sepharose is to increase the 
concentration of ammonium sulfate in the lysate to further expose the hydrophobic sites 
on αCD22scFv giving the protein a higher specificity to the resin. 
To increase the adsorption of αCD22scFv to Phenyl Sepharose resin, ammonium 
sulfate was added to clarified lysate to a final concentration of 1.5M ammonium sulfate. 
The lysate was batch purified with Phenyl Sepharose resin for 5, 15, 30, and 60 minutes 
at room temperature. Supernatants of the lysate after incubation with the resin was run 
on a Western Blot to determine how much protein was left in the supernatant; the first 
column volume of wash was also run on the Western Blot to determine non-specific 
binding to the column. After binding with the Phenyl Sepharose resin after the time 
points, the supernatants (Figure 29, Lanes 3, 5, 7, and 9) reveal a thick band on the 
Western blot. The washing fractions (Figure 29, Lanes 4, 6, 8, and 10) also contained 
significant amount of αCD22scFv. The Western Blot reveals that even at 1.5M 
ammonium sulfate, the hydrophobicity of αCD22scFv is not enough to bind to the HIC 
and even if the recombinant protein gets taken up during the load, it interacts weakly 
with the resin and easily comes off in the wash. Clarified lysates have many proteins that 
competitively interact with Phenyl Sepharose resin. For αCD22scFv to have a strong 
affinity to the HIC resin, the protein needs: (a) more binding sites on the resin to 
accommodate all the proteins that have an affinity to the resin (increasing bed volume) 
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and/or (b) reduce the amount of competing proteins in solution (different pretreatment 
methods). By increasing the concentration of ammonium sulfate in the clarified lysate 
from 1M to 1.5M, about half of αCD22scFv is lost due to precipitation. Even though 
increasing the concentration of ammonium sulfate could further increase the specificity 
of αCD22scFv to the resin, a majority of the protein will be lost before the capture 
chromatography step and is, therefore, not a viable option as a capture chromatography 
step. However, Phenyl Sepharose resin could be used as an intermediate purification 
step.  
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Figure 29. Uptake experiment with 1.5M ammonium sulfate and Phenyl Sepharose 
resin. Western blot analysis of αCD22scFv, using anti-FLAG-AP conjugated antibody. 
Lane 1: supernatant of clarified lysate; Lane 2: Supernatant after 1.5M sodium phosphate 
precipitation; Lane 3: supernatant after 5 minutes of binding with Phenyl Sepharose 
resin; Lane 4: wash of Phenyl Sepharose resin after 5 minutes of incubation with 
supernatant; Lane 5: supernatant after 15 minutes of binding with Phenyl Sepharose 
resin; Lane 6: wash of Phenyl Sepharose resin after 15 minutes of incubation with 
supernatant; Lane 7: supernatant after 30 minutes of binding with Phenyl Sepharose 
resin; Lane 8: wash of Phenyl Sepharose resin after 30 minutes of incubation with 
supernatant; Lane 9: supernatant after 60 minutes of binding with Phenyl Sepharose 
resin; Lane 10: wash of Phenyl Sepharose resin after 30 minutes of incubation with 
supernatant. 
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Appendix III 2-D electrophoresis of FLAG-purified αCD22scFv 
The Texas A&M Protein Chemistry lab ran FLAG-purified αCD22scFv on a 2D 
electrophoresis gel (Figure 30). The gel reveals a very pure sample with a protein train 
consisting of highly purified αCD22scFv. The protein train shows that αCD22scFv has 
several differently charged variants.  
 
 
 
Figure 30. 2D electrophoresis gel on FLAG-purified αCD22scFv. 
 
